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Abstract 
The identification of autoantibodies is a primary diagnostic marker for the diagnosis of 
some autoimmune diseases. The sera of patients with connective tissue diseases 
commonly contain autoantibodies that target nuclear antigens. As such these 
antibodies are called antinuclear antibodies (ANAs). Furthermore, the clinical 
identification of ANAs in patient sera to specific nuclear antigens is a primary tool for 
the diagnosis of connective tissue diseases. For this purpose specific extractable 
nuclear antigens (ENAs) are used. The most commonly employed laboratory 
technique for the detection of ENA antibodies is the enzyme linked immunoabsorbant 
assay (ELISA). ELISA is a simple technique that can be automated and provides high 
diagnostic sensitivity for the detection of ENA antibodies comparatively to a counter 
immunoelectrophoresis (CIE) assay. However, compared to CIE ELISA lacks 
diagnostic specificity. Therefore there is a demand for an assay with high diagnostic 
specificity as a secondary diagnostic test for the detection of ENA antibodies. The 
central aim of this project was to develop and validate a novel CIE assay that used 
fluorescently labelled ENAs to detect ENA antibodies in patient serum. 
 
Development of the assay began with comparative testing of fluorescently labelled 
and unlabelled antigens to confirm that the immunochemical properties of the antigen 
remained intact. The CIE assay conditions were optimised for the detection of four 
ANAs SSA, SSB, RNP/Sm, and Sm using their corresponding ENAs. Assay 
conditions optimised were flurophore type, gel composition, buffer composition, 
antigen concentration, the running time, and analytical specificity. 
 
Evaluation of 281 clinical sera samples known to have previously tested positive test 
by ANA indirect immunofluorescence were performed using the optimised CIE assay 
and ELISA.  The inter-rater agreement between the CIE assay and ELISA results 
was determined. Clinical details were used to retrospectively classify the clinical sera 
samples into clinical categories and case groups. This data was used for the 
diagnostic comparison of the CIE assay and ELISA results. 
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There was strong inter-rater agreement between the SSA CIE assay and ELISA 
results. The diagnostic specificity and positive likelihood ratio values of the SSA CIE 
assay were superior to those of the ELISA, while diagnostic sensitivity and the 
negative likelihood ratio values were approximately the same. There was strong inter-
rater agreement between the RNP/Sm CIE assay and ELISA. However, it was 
observed that the statistical measures of assay accuracy (diagnostic specificity and 
sensitivity, positive likelihood ratio, and negative likelihood ratio) for the RNP/Sm 
ELISA were superior to those of CIE assay. The diagnostic specificity of the SSB and 
Sm CIE assays were higher than that of their respective ELISAs. This was also true 
for the positive likelihood ratio values of the SSB and Sm CIE assays when 
compared to their respect ELISAs.  
 
The SSA CIE assay results suggest that this assay maybe a suitable replacement for 
ELISA as a diagnostic tool for the identification of anti-SSA antibodies and Sjogren’s 
syndrome. The SSB and Sm CIE assay results suggest that these assays would be 
suitable as secondary confirmatory diagnostic assays for the identification of their 
respective ENA antibodies. However, further performance evaluation of the assays 
within a routine diagnostic laboratory is required.  
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1. Introduction 
Autoimmunity is when the body’s immune system targets the body’s own molecular 
components which then results in an autoimmune disease. There are more than 70 
different autoimmune disease disorders that affect approximately 5% of the 
population of western countries (Lleo et al., 2010). There can be no discussion of 
autoimmunity without a grounded understanding of the immune system. 
 
1.1 The Immune system 
The immune system has evolved a highly complex series of innate and adaptive 
mechanisms to ward off pathogens and disease, and involves numerous interactions 
across a wide range of cells, soluble components, and tissues. The innate immune 
system reacts to possible pathogens in a non-specific manner. The first components 
of the innate immune system are the physical barriers such as connective tissue and 
epithelial cells that prevent entry of pathogens into the host body. The innate cellular 
response is initiated by the recognition of conserved pathogen molecular motifs by 
pattern recognition receptors (PRRs). The cellular response includes phagocytosis of 
pathogens and foreign molecules, the release of toxic chemicals (hydrogen peroxide 
and hypochlorite) to kill pathogens, and the release of inflammatory mediates such as 
the cytokines tumor necrosis factor and interleukin-1 (IL-1) at the site of infection or 
trauma (Paul, 2013). The other major component of the innate immune response is 
the complement system and is a series of circulating proteins that bind to the surface 
molecules of pathogens. Complement binding in the innate immune response acts 
either via the alternative pathway, beginning when the C3b complement protein binds 
to the surface molecule of a pathogen (Paul, 2013) or via the Mannin-binding lectin 
pathway. This binding attracts the other complement proteins that form a complex 
initiating one of several immune responses (complement also complexes with surface 
bound antibodies by the classical pathway). 
 
The adaptive immune system is a highly complex and ordered response to the 
presence of specific molecule (antigens) within the host. The adaptive immune 
response begins with the uptake of antigen and presentation of antigenic peptides. 
Antigens in the body are picked up by the Antigen Presenting Cells (APCs) and 
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presented via the major histocompatibility complex (MHC) molecule to the T-cells, 
activating them and initiating the adaptive immune response. There are two classes 
of MHC molecule and the molecule that is used to present antigen depends on the 
source of the antigen (Paul, 2013). Extracellular antigens such from bacteria, 
parasites, and toxins that are phagocytosed, degraded, and then presented by MHC 
class II: intracellular antigens such as viral proteins, intracellular bacteria, and tumor 
antigens are digested internally and presented via MHC class I. Antigen presentation 
via MHC class II is carried out by dendritic cells (DCs), macrophages, and B-cells; 
while most cells in the body can present antigen via MHC class I. T-cells interact with 
the antigen-MHC via specific T-cell receptors (TCRs) on the surface of T-cells (Hsieh 
et al, 2013). This interaction along with interactions between co-stimulatory 
molecules/receptors present on APCs and T-cells, as well as soluble factors such as 
cytokines mediate the activation of T-cells (Paul, 2013). Activated T-cells proliferate 
and up-regulate the immune response to remove the source of the antigen from the 
host. 
 
T-cells can be divided into subpopulations based on their role and identifying surface 
molecules. One of the primary markers of T-cell population subdivision is between 
the CD8+ and CD4+ surface molecules (Paul, 2013). Naive populations of these cells 
can be found within the lymph nodes. These cells are activated upon presentation 
with antigen by APCs. Naive CD4+ T-cells upon presentation with antigen can 
differentiate into T-helper (TH) cells and depending on the co-stimulatory signal 
provided by the APC differentiate into TH1 or TH2 cells (Mills, 2004). TH cells primary 
role in the adaptive immune response is to release cytokines to modify and direct the 
activity of the other immune cells (Paul, 2013). TH2 cells release the cytokines IL-4, 
IL-5, and IL-6 which induces B-cell proliferation, antibody (Ab) class switching, and 
Ab production; TH1 cells produce the cytokine interferon-ϒ that actives the 
antimicrobial killing activity of macrophages and induce CD8+ T-cells to proliferate 
(Mills, 2004). In order for the TCR to interact with MHC class I the T-cell must be 
CD8+ (Paul, 2013). These CD8+ T-cells are also known as cytoxic T-cells as upon 
TCR-MHC-class I interaction, and a co-stimulatory signal (either from directly from 
APCs or indirectly from TH1) these cells release a number of cytotoxic chemicals that 
kill infected cells. There is another group of T-cells known T-regulatory cells (Treg) that 
are identified by the presence of the FoxP3+ and play a major role in the regulation of 
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immunity and autoimmunity as they can down-regulate the immune response at 
many key steps (Mills, 2004; Roncarolo & Battaglia, 2007). 
 
B-cells are the antibody (Ab) producing cells of the adaptive immune system. Like the 
T-cell’s TCR the B-cell has a B-cell receptor (BCR) that is able to bind and recognize 
antigens (Paul, 2013). Unlike the TCR the BCR can recognise native antigen (antigen 
that has not been processed by an APC) (McHeyzer-Williams & McHeyzer-Williams, 
2005). The development of the B-cell begins with immature B-cells being produced in 
the bone-marrow (Paul, 2013). They then migrate to the secondary lymphoid tissues 
and blood. These cells are still naive and although the specificity of their BCR is fixed  
changes in affinity occur through somatic hypermutation (Goodnow et al., 2005). 
Upon binding of native antigen to the BC, and followed by co-stimulation from a TH 
cell within lymphoid tissues, the B-cell undergoes rapid clonal expansion and 
diversification of its BCR (McHeyzer-Williams & McHeyzer-Williams, 2005).  
Diversification of the BCR occurs by a somatic hypermutation of the BCR variable 
region and creates a pool of BCR receptors each with slightly different affinity for the 
originally recognised antigen (Melamed et al., 1998). These cells then interact with 
the TH cell and if the interaction is sufficiently strong, co-stimulatory signals initiate B-
cell differentiation into either a plasma B cell or a memory B-cell (McHeyzer-Williams 
& McHeyzer-Williams, 2005). Both of these cell types having a fixed BCR. When 
antigen binds to the BCR of the plasma cell, the plasma cell secretes large quantities 
of antibodies. Memory cells are long lived and are primed to quickly proliferate in 
response to a secondary exposure to antigen.  
 
The specificity of antibodies produced by a B-cell is the same as its BCR (McHeyzer-
Williams & McHeyzer-Williams, 2005). The role of antibodies is to bind antigens, 
either individual molecules such as toxins, or antigens on the surface of a cell such 
as a pathogen or viral proteins attached to an infected cell (Paul, 2013). Antibody 
bound antigen is recognized by effector cells of the immune system to phagocytose 
the antigen or to release cytotoxic chemicals. Antibody as previously mentioned also 
acts as scaffold for complement binding. Another activity of antibody is to localise a 
foreign body by binding multiple antigen molecules simultaneously, forming a 
complex with limited mobility within the body.  
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1.1.1 Antigens 
An antigen can be any substance simple or complex, organic or inorganic that elicits, 
enhances or provokes an adaptive immune response. Antigens are classified into 
two general types exogenous antigens and endogenous antigens. Exogenous 
antigens enter the individual from the environment i.e. microorganisms, bacterial, 
pollens, drugs, and pollutants (Vaman Rao, 2006). Endogenous antigens however 
are found within the individual and can be sub-divided into three categories.  
 
1. Xenogenic Antigens also known as heterogenic antigens (Vaman Rao, 2006) 
these are antigens that are common to a number of species. Thus sera will 
cross-react with cells or fluids of many different species of animal and or 
microorganisms. The most well-known of these is the Forssman antigen, 
which is can be found on red blood cells of many species, as well as bacteria 
(Vaman Rao, 2006).  
 
2. Autologous antigens: These are self antigens and are normally not 
immunogenic. However these can become immunogenic and cause the host 
to mount an immune response to its own tissues.  
 
3. Allogenic Antigens; These are antigens from the same species yet due to 
genetic differences allow differentiation of individuals. An example of this are 
the ABO blood group antigens. 
 
Generalized properties that influence the level of immunogenicity of an antigen are 
1. Foreignness: As a correctly functioning host immune system has generally 
been screened against self antigens the degree to which the substance is 
genetically foreign to the host will affect the level of immunogenicity the 
antigen induces. 
 
2. Molecular size is important as effective immunogens have a size greater than 
10 kDa with the best immunogens having a mass of approximately 100 kDa 
(Vaman Rao, 2006). 
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3. Heterogeneity and subsequent chemical composition of an immunogenic 
molecule is important as synthetic homopolymers are not immunogenic while 
large co-polymers can be immunogenic especially if aromatic amino acids are 
added (Bhattacharya & Sinha, 2006). Also for proteins the primary structure is 
a primary determinant of immunogenicity with the complex secondary, tertiary, 
and quaternary structures additionally increasing immunogenicity. 
 
4. The physical form of the antigen is important.  Denatured proteins, and 
insoluble macromolecules are strongly immunogenic as they are more likely to 
be targeted by the antigen presenting cells (Bhattacharya & Sinha, 2006).  
 
5. Degradability of a molecule is important for determining the immunogenicity of 
an antigen (Paul, 2013). An increased ability of APC to degrade a molecule so 
that has been phagocytosed and have its components present to T-helper 
cells increases the likely hood it will elicit an immunogenic response. 
 
1.1.2 Antibodies 
Serum proteins are classified electrophoretically into major groups by increasing 
isoelectric point (decreasing mobility) as pre-albumins, albumin, alpha-globulins, 
beta-globulins, gamma-globulins, and basic proteins. In turn these are sub classified 
by function, molecular size, solubility, and antigenic composition. Antibodies are 
gamma-globulins and can also be called immunoglobulins (Crowle, 1973). Although 
the definition of immunoglobulin extends to include molecules having patterns of 
molecular structure in common with antibodies such as major histocompatibility 
complex (MHC) and T-Cell receptors which also bind antigen (Elgert, 1996). 
Immunoglobulins (Ig) can be classified into 5 classes IgG, IgM, IgD, IgA, and IgE. 
Despite their diversity, the family of immunoglobulins have common properties. 
Circulating antibodies produced are of a polyclonal nature (Vaman Rao, 2006).  
 
In the 1950s and 60s experiments by Porter and Edelman revealed the basic 
structure of the immunoglobulin molecule for which they jointly received the Nobel 
prize . Edelman treated the most basic immunoglobulin IgG with dithiothreitol to 
disrupt the disulphide bonds in the presence of iodoacetamide to prevent re-
association of the disrupted bonds. This revealed two subunits a heavy 51.6 kDa 
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subunit and a light 23.5 kDa subunit. These subunits are known today as the heavy 
and light chains of the IgG molecule. Edelman also concluded that the complete IgG 
molecule is 154 kDa and is composed of two heavy subunits and two light subunits 
(Edelman et al., 1968). 
 
Porter’s experiments involved hydrolyzing the peptide bonds of rabbit IgG with the 
proteolytic enzyme papain in the presence of the reducing agent to cysteine (Elgert, 
1996; Kerr, 2006; Porter, 1959). This produced three fragments identified by 
chromatography. Two of the fragments had similar size ~50 kDa and a very similar 
amino acid content. These two fragments were named the Fab fragments (fragments 
of antigen binding) as they retained the ability to bind antigen although they lost the 
ability to precipitate. The third fragment was heavy and could not bind antigen was 
named the Fc fragment (fragment crystallisable) for it crystallised during cold storage. 
Thus, Porter determined that the IgG structure consisted of two similar antigen-
binding structures linked to a third structure. 
 
Thus all antibodies consist of two light chains and two heavy chain with the type of 
heavy chain determining the antibody class. All antibodies have a variable region 
responsible for antigen binding, and a constant region of which the Fc portion is 
recognized by the effector cells of the immune system i.e. macrophages. The 
variable domain of the heavy chain consists of 3 segments labelled V, D, and J. To 
produce antibodies specific to the infinitely diverse set of possible antigens the body 
may be exposed to, the genes encoding these segments repeatedly undergo 
recombination events. This is known as VDJ recombination and produces an equally 
large set of possible antibodies. The light chain also undergoes similar recombination 
however there are only two segments V and J. 
 
1.1.3 Antigen-Antibody Interactions 
The antibody (Ab) and antigen (Ag) interaction is non-equivalent with the antigenic 
epitopes interacting with the variable domain of the antibody molecule, particularly 
the hypervariable region or complement determining region (CDR). The antigen-
antibody interaction is a non-covalent reaction. It is due to individually weak forces 
that cumulatively form a strong specific interaction sufficient to prevent dissociation 
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but weak enough to allow some reversibility. These weak forces are hydrogen bonds, 
van der Waals interactions, ionic bonds, and hydrophobic interactions.  
 
However, occasionally weak and often nonspecific unstable antigen-antibody 
complexes are formed (Vaman Rao, 2006). Non-specific cross reactivity with 
unrelated antibodies is possible only when two different antigens share similar 
epitopes or antibodies specific for one epitope also bind to an unrelated epitope 
possessing similar chemical properties (Vaman Rao, 2006). 
 
Affinity at one binding site does not always reflect the true strength of the antibody-
antigen interaction. The strength of multiple interactions between a multivalent 
antibody (IgM) and antigen is called avidity, as opposed to affinity, which describes 
the strength of single interaction at one binding site. The avidity of an antibody is its 
capacity to form a stable complex.  It is observed that high avidity compensates for 
low affinity as is the case of IgM has low affinity but has high avidity because of its 10 
weak binding sites (Vaman Rao, 2006). 
 
1.1.4 Tolerance 
The immune system is able to differentiate between self and non-self components. 
This is known as self tolerance and is mediated by a complex process known as 
clonal selection that augments T and B lymphocytes populations to discriminate 
between self and non self antigens. Clonal selection of T-lymphocytes occurs in the 
thymus and has two primary steps (Klein et al., 2009). In the first selection step the 
lymphocyte TCR is exposed to a antigen-MHC complex expressed on cortical thymic 
epithelial cells and selection is based on the TCR’s affinity for antigen-MHC. TCRs 
that have a moderate to high affinity for antigen-MHC are positively selected and 
move on to the second stage of selection: those with no or very low affinity for 
antigen-MHC are neglected and die (apoptosis). In the second step of selection the 
TCRs are exposed to MHC bound self antigens that are expressed by medulla 
cortical thymic epithelial cells and antigens presented by DCs. TCRs that have a 
moderate to high affinity to the antigen-MHC complex are actively deleted by 
apoptosis (negative selection). The majority of the remaining T-cell population has a 
low to moderate affinity for MHC and no affinity for self antigens. There does remain 
a small population of T-cells that have a low affinity for self antigen and post-
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thymically they develop into TReg  cells that play a major role in regulating immunity 
and suppressing autoimmunity (Mills, 2004). 
  
The B-cell lymphocytes also go through a process of clonal selection throughout their 
development (Goodnow et al., 2010). The BCR of a naive B-cell in the bone marrow 
that binds self antigen will halt its maturation, internalise the BCR, and initiate VDJ 
recombination. Unless the B-cell can produce a new BCR that is not self reactive the 
cell will die in 1-2 days (Goodnow et al., 2005). After leaving the marrow, B-cells 
acquire sensitivity to antigen-mediated apoptosis, such that if antigen binds to the 
BCR without a co-stimulatory signal the B-cell will possibly undergo paralysis 
followed by apoptosis (Melamed et al., 1998). However if the B-cell receives a co-
stimulatory signal from a TH cell after binding the antigen the co-stimulatory signal will 
cause the B-cell to proliferate instead of arrest, since the co-stimulatory signaling 
relies on the TH cell to have undergone thymic selection and not be self-reactive. 
 
1.2 Autoimmunity and autoimmune disease 
 
1.2.1 Loss of tolerance and autoimmunity 
Some individuals lose tolerance as the fine-tuning of the immune system to self and 
non-self antigens fails and leads to an autoimmune disease. Although a number of 
genetic sequences have shown to be associated with autoimmunity they have at this 
point provided little clinical significance (Selmi, 2011). Rather, the loss of tolerance is 
attributed to a complex interaction between genetics, and what are mostly 
unspecified environmental factors such as drug interaction, and infection (Gomez-
Puertaet al, 2008; Lleo et al., 2010). Although there is little evidence showing specific 
mechanisms that induce a specific autoimmune disease, there are a number of 
known mechanisms of tolerance failure.  
 
There are several mechanisms of activation of self-specific B-cells via TH cells. It has 
been shown that B-cells bind to membrane bound IgG and produce IgG 
autoantibodies (rheumatoid factors) that can be activated by TH cells after the B-cell 
has phagocytosed an Ag-Ab complex (Roosnek & Lanzavecchia, 1991). The key to 
this is that when the B-cell with a BCR specific for the IgG antigenic peptide, 
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recognises and phagocytoses the associated Ag-Ab complex, the peptide that is 
presented by the B-Cell to the TH cell can be any peptide present in the Ag-Ab 
complex. Similarly TH cells that have been activated and are responding to foreign 
antigen can be misdirected to self reactive BCRs that cross-react with a component 
of the foreign antigen (Goodnow et al., 2005). This concept that a foreign antigen, 
sharing some similar epitopes to a self antigen, can induce autoimmunity is known as 
molecular mimicry. A well known example of autoimmunity induced following 
bacterial infection and attributed to molecular mimicry is that of rheumatic fever. 
However, no specific antigen has been identified as the cause.  
 
It is known that bacterial macromolecules e.g. lipopolysaccharides can act as ligands 
for the co-stimulatory receptor substituting the T-cell signal needed for B-cell 
proliferation (Goodnow et al., 2005). The substitution of co-stimulatory signals by 
some bacterial antigens can also cause T-cell activation by activating immature DCs 
to release T-cell activating signals or by directly by passing the co-stimulatory signals 
of APCs (Mills, 2011). The activation of immune cells through a co-stimulatory signal 
is the theoretical mechanism attributed to adjuvant function. 
 
Problems in BCR editing have been associated with autoimmune disease.  In the 
case of the autoimmune disease systemic lupus erythematosus (SLE), most of the 
anti-double-stranded (anti-DS) DNA antibodies are somatically mutated indicating a 
problem with regulation of self-reactive receptors (Goodnow et al., 2005). 
Additionally, anti-nuclear and anti-DS DNA autoantibodies like those found in SLE are 
more frequently borne by a subset of B-cells with little or no surface BCR in human 
bone marrow (Goodnow et al., 2005). This indicates that there has been some failure 
to edit or delete these self-reactive BCR-producing B-cells. 
 
The role of TReg cells is to suppress the immune response produced other self-
antigen reactive immune cells. As such, defects in TReg cells are associated with 
autoimmune disease and experimental suppression of TReg activity has been shown 
to exacerbate autoimmune effects within the host (Roncarolo & Battaglia, 2007).  
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1.2.2 Autoimmune diseases 
Autoimmune diseases can be divided into two broad categories organ specific and 
systemic autoimmune diseases (Vaman Rao, 2006). In an organ specific 
autoimmune disease the immune response is directed against a specific antigen 
corresponding to a single organ. There are several mechanisms of organ specific 
autoimmune disease such as humoral or cell mediated attack of the organ causing 
severe cellular damage as is the case in type 1 diabetes where by the immune 
system targets and destroys the insulin producing beta-cells of the pancreas, thus 
inducing diabetes (Paul, 2013). Rather than destroying organ function, auto-immunity 
may induce hyperactivity of an organ. In Graves’ disease autoimmunity induces 
hyperthyroidism as autoantibodies bind to the thyroid-stimulating hormone receptors 
(TSH-Rs), and induce thyroid hormone production and thyroid growth (Paul, 2013). 
Autoantibodies may conversely block a function preformed by the cell or organ as in 
the case of Addison’s disease (Vaman Rao, 2006) whereby autoimmune destruction 
of the adrenal cells results in insufficient hormone production.  
 
For systemic autoimmune diseases, conversely the autoantibodies are directed 
against broad range of antigen and target organs. This is caused by defective 
immune regulation of T and B-lymphocytes, which leads to widespread tissue 
damage from cell mediated and humoral antibodies as well immune complex 
mediated response (Vaman Rao, 2006). Examples of such diseases are connective 
tissue diseases such as SLE, systemic sclerosis (SSc), Sjogren’s syndrome (SS), 
polymyositis/dermatomyositis (Abbreviated PM/DM and also known as idiopathic 
inflammatory myopathies).  
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1.3 Autoantibodies 
The detection of specific antibodies in the serum of patients is a pillar of diagnosis 
and management for some autoimmune diseases. For connective tissue diseases 
(CTDs) such as SLE the detection of autoantibodies to specific nuclear antigens is 
used as a primary clinical diagnostic feature. Antibodies that react with nuclear 
antigens are known as antinuclear antibodies (ANAs). The presence of specific ANAs 
can be used as a predictive marker for the disease and patient outcome (Gomez-
Puerta et al., 2008; Hernandez-Molina et al., 2011), particularly as patients can 
present autoantibodies many years before they show clinical symptoms of disease. 
Anti-RNP antibodies and a lack of kidney involvement in SLE is an indicator of a 
favorable patient outcome (Shoenfeld & Tincani, 2005). However, changes in 
autoantibody titer can often do not correlate with a patient’s clinical situation: low 
ANA titer is associated with SLE, high titers can found in healthy patients (Shmerling, 
2005), and autoantibodies can persist when a patient is in remission (Shoenfeld & 
Tincani, 2005). This lack of correlation between disease and antibody titer may be 
because some autoantibodies such as many of 116 associated with SLE are not 
actually a causative agent of the autoimmune disease but are rather an 
epiphenomenon (Shoenfeld & Tincani, 2005). This can make the clinical utility of 
autoantibody detection questionable. In a comprehensive review by Sheldon (2004) it 
was recommended that autoantibodies be considered markers of disease and only 
tool that is part of a larger diagnostic panel.  
 
It is common for patients displaying symptoms of autoimmunity to test positive for 
more than one autoantibody (Defendenti et al., 2011). Anti-SSA (also known as anti-
Ro) and/or anti-SSB (also known as anti-La) antibodies are the primary serological 
markers in the diagnosis of SS and SLE with patients presenting precipitating 
antibodies in 60% and 40% respectively of SS patients, and 35% and 15% 
respectively of SLE patients (Manoussakis et al., 1995; Reichlin & Harley, 1986).  
Also, in the case of SS, the antibody profile is fixed at an early stage of the disease 
(Hernandez-Molina et al., 2011). Anti-SSA antibodies are also associated with 3-11% 
of patients with SSc and 5-15% of patients with PM/DM (Franceschini & Cavazzana, 
2005). The SSA complex is a ribonuclear protein complex containing hY-RNAs, and 
52 kDA and 60kDA protein subunits. The SSB molecule is composed of a highly 
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conserved 48 kDa nuclear protein that is capable of associating with various small 
RNAs, including precursor transcripts of RNA pol III (Manoussakis et al., 1995). The 
Ro/SSA complex has been identified as an E3 ligase that negatively regulates 
cytokine production induced by the IFN-gamma pathway and the SSB protein works 
as a transcription termination factor of RNA polymerase III (RNA pol III) (Hernandez-
Molina et al., 2011).  
 
Other ANA include anti-Sm which is seen in 25-30% of SLE cases (Colglazier & 
Sutej, 2005). The anti-Sm antibody binds to a series of 7 small proteins that complex 
with 4 small RNAs to form a small nuclear ribonucleoprotein (snRNP) complex 
(Migliorini et al., 2005). The anti-RNP antibody binds the U1-RNP complex is another 
snRNP composed of 3 proteins and the U1-RNA (Sheldon, 2004). The Sm and RNP 
snRNP complexes are found in the nuclei of all eukaryote cells and function together 
as a spliceosome (Migliorini et al., 2005). The anti-Sm antibodies are associated with 
approximately 30% of North American and 5% of European SLE patients and anti-
RNP antibodies are detectable in 25-47% of all SLE patients (Migliorini et al., 2005). 
The anti-RNP antibodies are associated with mixed connective tissue diseases 
consisting of a combination of SLE, SSc, and polymyositis: the nature of mixed 
connective tissue disease means the prevalence of anti-RNP antibodies cannot be 
calculated (Colglazier & Sutej, 2005). Anti-RNP and anti-Sm antibodies can also be 
found in 2% and 1% respectively of SS patients (Nardi et al., 2006). Like SSA and 
SSB it is common for patients to be have both anti-RNP and anti-Sm antibodies, with 
anti-Sm nearly always associated with anti-RNP antibodies (Migliorini et al., 2005). 
Anti-Scl-70 antibodies target topoisomerase I and occur in 20% of patients with 
diffuse SSc (Colglazier & Sutej, 2005). Anti-Jo-1 antibodies target the histidyl-tRNA 
synthetase and their presence is found in interstitial lung disease and PM/DM 
(Bernstein et al., 1984). 
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1.4 Antinuclear antigen antibody testing 
 
1.4.1 Whole cell screening of ANAs 
In 1948 the L.E. cell was identified and described in the bone-marrow preparations of 
patients with SLE (Hargraves et al., 1948). The lupus erythematous cell (LE cell) is a 
polymorphonuclear leucocyte that contains cell nuclei that have been phagocytosed 
and digested (Hepburn, 2001). In 1949, experiments by Haserick and Bortz added 
plasma from patients with SLE to bone marrow preparations from normal subjects 
and these results were compared to bone-marrow preparations using plasma from 
the same healthy subjects (Haserick & Bortz, 1949). The plasma from patients with 
SLE induced the LE cell phenomenon while plasma in the control group failed to 
produce the phenomenon. The LE cell phenomenon was used as a primary 
diagnosis test for SLE (Hepburn, 2001). 
 
The whole cell detection of ANAs is now done by an indirect immunofluorescence 
(IIF) assay (Hepburn, 2001: Keren, 2002). In this assay Hep-2 cells are fixed on a 
slide and then incubated with patient serum. After washing a conjugated anti-human 
antibody labelled with a fluorophore is then added and binds to the patient 
autoantibodies bound to the cell nucleus. Slides are examined using fluorescent 
microscopy to examine the nuclear fluorescent staining pattern. The type of staining 
pattern correlates with patient diagnosis and can be used to diagnose autoimmune 
disease (Keren, 2002). A homogenous staining pattern indicates anti-DNA antibodies 
and is associated with SLE A diffuse staining pattern indicates either anti Scl-70 
antibodies that are associated with SSc, or anti-histone antibodies that are 
associated with SLE and drug induce lupus (Sheldon, 2004). A speckled staining 
pattern indicates the presence of antibodies to extractable nuclear antigens (ENAs) 
such as RNP, Sm, SSA, and SSB (Sheldon, 2004). A cytoplasmic staining pattern is 
associated with anti-Jo-1 antibodies (Sheldon, 2004). 
 
The performance of ANA screening by IIF is difficult to assess as the method, 
substrate, and population subset differs between laboratories (Colglazier & Sutej, 
2005; Solomon et al., 2002). ANA IIF screening also tends to produce a high number 
of false positives and this limits its utility as a screening test (Colglazier & Sutej, 
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2005; Solomon et al., 2002). ANA IIF screening can also miss some critical antigen 
specificities notably anti-SSA and anti-Jo-1, as the antigens are poorly expressed or 
are not conserved in the cell line (Dahle et al., 2004; Sheldon, 2004). Regardless of 
these flaws, ANA IIF screening is still a widely used technique for the detection of 
ANAs. 
 
1.4.2 Detection of autoantibodies to extractable nuclear antigens 
There are several diagnostic techniques available for the detection of autoantibodies 
using ENAs rather than using whole cells. These include gel immunoprecipitation 
methods, double immunodiffusion (DID) and counter immunoelectrophoresis (CIE), 
the enzyme-linked immunosorbent assay (ELISA), the line immunoassay (LIA), 
immunoblotting (IB), and RNA precipitation. None of the methods can be considered 
to be a gold standard diagnostic method as each technique has practical and 
analytical advantages and disadvantages in respect to the other techniques. Also the 
standardisation of the techniques is difficult due to:variation in the antigen source and 
preparation; variations in antibody affinity in patient samples and standard samples; 
differences in methodology between laboratories (Sheldon, 2004).   
 
The prevalence of anti-ENA antibodies is low in the general population (Shmerling, 
2005) and current tests have a low positive predictive value and thus it is 
recommended that for patients suspected of having an autoimmune CTD that there 
be a two stage testing process (Phan et al., 2002): An initial highly sensitive 
screening test to identify all possible autoimmune patients with anti-ENA antibodies, 
followed by a highly specific assay (low false positives) that will confirm the presence 
of anti-ENA antibodies 
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1.5 Comparison of diagnostic screening methods 
 
1.5.1 Statistical considerations 
In order to determine whether an assay is of clinical utility as a diagnostic screening 
test a number of statistical analyses can be done. The diagnostic sensitivity and 
specificity of an assay (Table 1) are two crucial statistical parameters used to assess 
the practical effectiveness/accuracy of an assay, as they are independent of disease 
prevalence. Diagnostic sensitivity measures the proportion of positives that are actual 
true positive results. Diagnostic specificity measures the proportion of negative 
results that are actually true negatives.  
 
Another set of useful statistics for assessing the diagnostic utility of an assay are 
positive predictive value (PPV) that measures the proportion of samples that are true 
positives, and the negative predictive value (NPV) that measures the proportion of 
true negatives. Thus these two statistics are measure of diagnostic perfomance. 
However PPV and NPV are only applicable to the study population from which they 
were derived and the PPV and NPV quoted for one study’s population sample are 
consequently not directly transferable to another study’s sample population (Phan et 
al., 2002). PPV and NPV should only be used to assess an assay if the number of 
the true positives (truly healthy patients) and the number of true negatives (patients 
that truly have the disease) used during diagnostic testing matches the prevalence of 
the disease in true population.  
 
The likelihood ratio (LR) should be used instead of than NPV and PPV, as it depends 
on the prevalence of the disease. There are two LRs that can be calculated (Table 2). 
The positive LR (PLR) is the probability of a person who has the disease testing 
positive and the negative LR (NLR) is the probability of a person with the disease 
testing negative. For example, a PLR of 5 indicates that a person with the disease is 
5 times more likely to produce a positive result than a person without the disease. LR 
values higher than 10 and less than 0.1 indicate a positive or negative confirmatory 
diagnoses respectively and LR values close to 1 provide no clinical value as the test 
does not change the odds of identifying the disease (Deeks & Altman, 2004).  
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In reporting the agreement between different methods of anti-ENA detection the 
kappa-statistic should be used (Phan et al., 2002). The kappa-statistic gives a 
measure of how strongly the inter-rater agreement is between two observations, such 
as the agreement of results between two different assays. A strong agreement 
indicates that any difference between two observations (assay results) is not caused 
by the observers (assay techniques). A weak agreement indicates that the difference 
in observations is due to the observers. The Cohens kappa value can be interpreted 
as follows; 0 as indicating no agreement, 0–0.2 as slight, 0.21–0.4 as fair, 0.41–0.6 
as moderate, 0.61–0.8 as substantial, and 0.81–1 as strong agreement (Kraemer, 
1980; Landis & Koch, 1977). 
 
	  	   	  	   	  	   	  	   	  	  
	   	  
Patient	  condition	  as	  determined	  by	  
clinical	  benchmark	   	  
	   	  
Condition	  Positive	   Condition	  Negative	  
	  
Patient	  test	  
results	  from	  the	  
diagnostic	  test	  
being	  evaluated	  
Test	  
Positive	  
True	  Positive	  (TP)	   False	  Positive	  (FP)	  
Positive	  predictive	  value	  	  	  	  	  
=	  TP	  /	  (TP	  +	  FP)	  
Test	  
Negative	  
False	  Negative	  
(FP)	  
True	  Negative	  (TN)	  
Negative	  predictive	  value	  
=	  TN	  /	  (TN	  +	  FN)	  
	   	  
Sensitivity	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
=	  TP	  /	  (TP	  +	  FN)	  
Specificity	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
=	  TN	  /	  (TN	  +	  FP)	   	  
	   	   	   	   	  
Table	  1.	  Relationship	  among	  statistical	  terms	  
 
 
Positive	  Likelihood	  Ratio	  (PLR)	  =	  Sensitivity	  /	  (1	  -­‐	  Specificity)	  
Negative	  Likelihood	  Ratio	  (NLR)	  =	  (1	  -­‐	  Sensitivity)	  /	  Specificity	  	  
Table	  2.	  Likelihood	  Ratio	  formula	  
 
 
1.5.2 ANA IIF 
Soloman et. al. (2002) collated and evaluated the published data on ANA IIF 
diagnostic testing. The calculated sensitivity, specificity, PLR, and NLR from this data 
(Colglazier & Sutej, 2005) for the diagnosis of select autoimmune diseases by ANA 
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IIF assay is shown in Table 3. Based on this data the sensitivity and PLR indicate 
that for SLE and SSc the ANA IIF assay would be suitable as an initial screening test. 
However all 4 CTDs have low specificity, a low NLR and thus have a high probability 
of producing a false positives result. These results confirm the need for a secondary 
alternative high specificity assay for CTD diagnosis. ANA IIF is also a labor intensive 
and time consuming assay that produces a subjective result (Keren, 2002).  
 
Disease	   Sensitivity	   Specificity	   Positive	  
likelihood	  ratio	  
Negative	  
likelihood	  ratio	  
Systemic	  lupus	  erythematosus	   93%	   57%	   2.2	   0.11	  
Scleroderma	   85%	   54%	   1.86	   0.27	  
Polymyositis/Dermatomyositis	   61%	   63%	   1.67	   0.61	  
Sjogren	  syndrome	   48%	   52%	   0.99	   1.01	  
	  	   	  	   	  	   	  	   	  	  
Table	  3.	  	  Statistical	  analysis	  of	  the	  diagnostic	  performance	  of	  the	  ANA	  IIF	  assay	  	  
Colglazier & Sutej, 2005	  
 
1.5.3 ELISA 
ELISA kits have become the most widely used method for anti-ENA antibody testing 
(Phan et al., 2002). A comparative study of 5 commercially available ELISA kits for 
anti-ENA testing indicated that ELISA is comparable and is some cases superior to 
ANA IIF (Tonuttia et al., 2004). ELISA assays have a number of inherent advantages 
that include rapid turnaround time, objective and quantitative results, and can be 
automated. ELISA is considered highly a sensitive assay for ENA detection with a 
lack of specificity comparably to other methods being its major flaw (Phan et al., 
2002). Also pure antigen is required or issues regarding lack of specificity are 
exacerbated (Phan et al., 2002). 
 
1.5.4 Immunoblotting 
The major advantage of IB is its ability to differentiate antibody interactions between 
different subunits of the same antigenic complex most notably between the 60-kDa 
and 52 kDa SSA subunits (Phan et al., 2002). A Loss of sensitivity is a problem for IB 
as proteins are denatured and therefore lose their conformational epitopes. 
Conformational epitopes are antibody binding sites that require tertiary and/or 
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secondary protein conformations to remain intact. A conformational epitope can form 
when a protein folds and peptides separated by sufficient space to prevent a specific 
antibody interaction are brought into close proximity to one-another allowing the 
antibody to bind. IB is also relatively expensive, and time consuming technique 
compared to CIE (Phan et al., 2002).  
 
1.5.5 RNA precipitation 
RNA precipitation is considered to have the highest sensitivity and specificity for the 
detection of anti-SSA and anti-SSB antibodies (Franceschini & Cavazzana, 2005). A 
comparative analysis of RNA precipitation, ELISA, IB, and CIE also identified RNA 
precipitation as having the highest specificity for anti-SSA and anti-SSB antibodies 
(Meilofet al, 1990). However the specificity and sensitivity of the CIE assay are 
comparable to those of the RNA precipitation assay. The authors also concluded that 
CIE was a better assay for routine diagnostics. A similar study performed by 
Manoussakis (1993) came to similar conclusions (Manoussakis et al., 1993) and both 
papers also reporting low specificities for ELISA. 
 
1.5.6 Immunoprecipitation; DID and CIE 
Immunoprecipitation methods have traditionally been a widely used method for the 
detection of ENA antibodies as they are highly accurate (Manoussakis et al., 1995). 
The quality of antigenic extract required for DID and CIE is quite robust and it is 
possible to use crude antigen homogenates for detection (Kveder & Bozic, 2002). 
CIE and DID have been shown to be a highly specific assay methods (Phan et al., 
2002). A comparative study by Phan et al (2001) of the CIE, ELISA, LIA concluded 
that the overall cost effectiveness of CIE is far superior to that of ELISA, and LIA 
(Phan et al., 2001). Also anti-ENA detected by CIE correlated better with their 
respective clinical diagnosis than anti-ENA detected by LIA and ELISA (Phan et al., 
2001).  
 
Manoussakis et al. (1995) compared the diagnostic sensitivity and specificity of CIE 
and Immunoblot to detect SSA and SSB antibodies in patients with SS and SLE. In 
this study detection of SSA and SSB for both CIE and immunoblot assays was shown 
to be highly specific (100%) for SS and SLE. Diagnostic sensitivity for SSB was the 
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same in both SS and SLE. However, the diagnostic sensitivity of the CIE assay was 
superior to immunoblot for the detection of SSA in both SS and SLE patients. 
 
The downside to both DID and CIE are that they are labour intensive and 
interpretation of results is dependent on the skill of the technician performing the 
assay. SSB due to a lack of conformational epitopes, and a low frequency of linear 
epitopes that tend to have a low antigenicity result in a reduced ability to precipitate 
and thus be detected by CIE or DID (Phan et al., 2002). The nature of the CIE assay 
itself can lead to a reduction in sensitivity for specific antigens. For example the Scl-
70 antigen is less negatively charged than other antigens and thus tends to move in 
the same direction as the patient antibodies towards the cathode. A technical 
advantage CIE has over DID is the time taken to reach assay completion (although 
this is dependent on the exact methodology of the two techniques). Also the 
sensitivity of CIE is superior to DID for the detection of SSA (Franceschini & 
Cavazzana, 2005).  
 
1.6 Counter Immunoelectrophoresis 
Counter immunoelectrophoresis also known, as countercurrent 
immunoelectrophoresis, is a rapid method used to examine reactivity between 
antigen and antibody. CIE takes advantage of the charge of the antigen and 
endosmotic flow to move antigen and antibody in opposite directions simultaneously 
so that analogous to a double diffusion test, they will meet, react and precipitate 
somewhere between their respective origins (Fig. 1) (Crowle, 1973). For this 
technique to work the antigen must be negatively charged, as to be 
electrophoretically drawn towards the anode and the antibody must be neutrally 
charged to be drawn by endosmotic flow towards the cathode.  
 
Figure 1 Diagrammatic representation of 
antigen and antibody migration during CIE  
The antigen (Ag) electrophoretically migrates 
towards the anode. The antibody (Ab) is drawn 
towards the cathode my endosmosis.  At the point 
the Ag front and the Ab front meet a precipitate 
forms. 
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There are many advantages to CIE over immunodiffusion methods; it is faster, more 
economical, more sensitive, can used with antigen molecules too large to simply 
diffuse quickly through agar gels and it can detect inefficient antibody which routine 
immunodiffusion tests form too diffuse and ephemeral a precipitate to be seen 
(Crowle, 1973). 
 
CIE although very rapid has its flaws. First there is little time for the visible second-
stage antigen-antibody complex to accumulate and result in precipitation. Also, both 
reactants migrate as finite zones (that match the shape of their origins) that rapidly 
collide with each other. This results in a limited range of antigen-antibody ratios that 
can occur during the brief interaction. Thus the optimal ratio of antigen to antibody 
required for precipitation (the equivalence zone) may not be achieved and so CIE is 
highly susceptible to adverse conditions of antibody and antigen excess (Crowle, 
1973). Also the wells need to be in line with each other to ensure the migrating zones 
don’t miss each other. Another disadvantage of CIE is due to the forces driving 
antibody and antigen in opposite directions precipitation may occur briefly and then 
reverse before it is been noticed (Crowle, 1973).  Some of these disadvantages can 
be minimized mechanically by using a lower voltage or higher ionic strength to lower 
the rate of migration; elongating wells increases the size of the migrating zone and 
thus creates a gradient of antibody-antigen interaction that will improve the chances 
of reaching equivalence. 
 
1.7 Chemical and physical processes 
 
1.7.1 Precipitation reactions 
Precipitins are antibodies which become insoluble after forming an antigen-antibody 
complex (Crowle, 1973). The reaction between soluble antigen and antibody leading 
to a visible precipitate is called the precipitin reaction or the precipitation reaction. 
The origin of precipitation reactions for the specific purpose of analysis of animal 
serum were developed by Oudin at the Pasteur Institute of Paris (Arquembourg, 
1975). Soluble antibody (animal serum) and antigen (proteins) were loaded into 
separate wells punched into a gel. The antigen and antibody were allowed to diffuse 
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through the gel, until the antigen and antibody diffusion fronts met. A visible 
precipitate would form due to the antigen and antibody interacting to form a complex. 
Ouchterlony added a second dimension to gel reactions; a third well that allowed for 
analysis of antigens from different sources (Arquembourg, 1975). Now known as 
Ouchterlony double diffusion, this technique allowed the identification of cross-
reactivity of the same antibody with different antigens (Identity), the identification of 
multiple antibodies in the same serum sample interaction with different antigens (non-
identity), and the identification of a single antibody recognizes common parts in 
structure between antigens from different sources, which are, for the rest of their 
constituents, different (partial identity) (Arquembourg, 1975).  
 
In the first stage of a precipitin reaction begins with the initial formation of a variety of 
invisible complexes. These complexes form as antibody and antigen collide and 
antibody binds to one of several ligands usually present on each antigen molecule. 
This is followed by formation of a lattice of soluble complexes that gradually expands 
into a visible precipitate due to antibodies interacting with the ligands of two separate 
antigens (Arquembourg, 1975; Crowle, 1973). In order to achieve antibody-antigen 
interactions at multiple reactive sites the antibody needs be bivalent, i.e. more than 
one Fab site should be available for reacting with antigen. Similarly antigen should be 
bivalent or polyvalent, i.e. it must have multiple epitopes available that can 
simultaneously react with different antibodies (Vaman Rao, 2006).  
 
Antigen-antibody reactions are not stoichiometric and in order to form a visible 
antigen-antibody precipitin, the concentrations of both antigen and antibody play an 
important role. An excess of either antigen or antibody will cause combining sites to 
become saturated and lead to insufficient lattice formation needed for precipitation 
(Arquembourg, 1975). When the antigen antibody ratio is optimal maximum 
precipitate will form which is called equivalence zone (Vaman Rao, 2006). When 
antigen-antibody precipitin reactions occur in a gel, a visible arc will form. The 
visibility of the precipitin arc will be greater at the center of the arc where 
optimal/equivalent antibody-antigen conditions exist, and visibility will fade towards 
the tips of the arc as the condition of antibody excess increases towards the edges of 
the precipitin arc (Arquembourg, 1975). 
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There are a number of other factors that affect the complex precipitation reaction that 
takes place between antigen and antibodies. These factors include non-antibody 
serum constituents such as lipids and serum complement proteins that improve 
precipitation; physiochemical conditions that fall outside optimal ranges of pH, salt 
concentration, and temperature antagonize precipitin formation; other non 
precipitating antibodies that have a weak avidity/affinity and possibly are non-specific 
for the antigen have been shown to help stabilize lattice formation (Crowle, 1973). 
Also certain ions such as Cd, Ni and barbital which precipitate lipids enhance Ag-Ab 
precipitation, and buffers that chelate such ions, like EDTA, Tris or citrate,depress it 
(Crowle, 1973).  
 
In the analysis of a complex mixture of antigens, gel diffusion reactions produced a 
series of precipitin bands concentrated in a small area in which recognition was 
impossible. Pierre Grabar then at the Pasteur Institute of Paris opened a third 
dimension. By submitting the antigen mixture to electrophoresis before carrying out 
the double immune diffusion reaction he separated the complex series of bands into 
a set of independent double diffusion reactions at locations imposed by ionization 
characteristics of antigens. (Arquembourg, 1975). 
 
1.7.2 Electrophoresis 
Electrophoresis can be defined as the movement of charged particles by direct 
current through an electrolyte solution. The basic apparatus required for gel 
electrophoresis consists of a power supply for direct current, positive and negative 
preferably non-polarizing electrodes, two vessel of buffer for immersing each 
electrode, that are separated by the supporting material (gel) in which electrophoresis 
will occur.  
 
When using gel electrophoresis the electrochemistry of the technique must be taken 
into account. In gel electrophoresis procedures, voltage (V) is the difference in 
electric potential between the two electrodes is held constant and the rate of 
migration of a molecule away from its point of origin is proportional to the voltage 
applied (Crowle, 1973). With voltage held constant the current (I) is determined by 
the conductance (G) of the buffer and medium divided by applied voltage. Resistance 
(R) is the reciprocal of conductance so any change in conductance will result in a 
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change in resistance. Wattage (W) in this instance can be considered a 
measurement of thermal output (heat) and will rise with any increase in current or 
resistance; however changes in current will have a greater exponential impact on 
temperature compared to resistance.  
 
V = IR 	  	  
G = I / V      R = V / I 
I = G / V       W = I2R 	  	  
Table	  4.	  Relationships	  between	  electrical	  formula	  
 
There are many factors that affect and need to be controlled in gel electrophoresis. 
Heat is a major consideration, as excessive heating will cause a number of problems. 
Such problems include disruption of the precipitin reaction, and evaporation of water 
leading to drying, shrinkage, and distortion of the electrophoretic gel medium. As 
previously mentioned, current is the main determining factor for temperature 
(Wattage). Thus, we can ascertain from the formula I = G /V (Table 4) that if voltage 
is constant, in order to keep current low, a buffer with low ionic strength (ionic 
strength is relative to conductance (G)) is needed. Importantly if evaporation occurs, 
solute concentration increases leading to an increase in current and thus an increase 
in temperature. 
 
The pH of the medium and buffer is important as it determines the charge of the 
proteins being electrophoresed. The overall net charge of a protein determines its 
direction and rate of movement through the medium. A protein composed of 
aminoacids with both acidic (carboxyl) and basic (amino) groups exposed can have a 
positive, negative, or neutral charge and needs to have a net electronegative charge 
in order to move towards the anode (Crowle, 1973). For this to occur the pH of the 
buffer needs to be higher than the isoelectric point of the protein. The isoelectric point 
is the pH at which a molecule carries no net electric charge i.e. it is neutrally charged. 
During electrophoresis pH change occurs as buffer salts are moved by electrolysis 
towards the cathode and anode driven by the current passing through the medium. 
Normally this is buffered well enough to prevent any significant pH change that will 
affect either the precipitation reaction or net charge of the proteins but if the current is 
excessive or buffering capacity is poor a significant change can occur (Crowle, 1973). 
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Also the flow of solutes towards the termini leads to an increase in their local 
concentration. Thus leading to local hotspots and increased evaporation at the 
termini (Crowle, 1973). 
 
The composition and physical characteristics of the gel medium all affect 
electrophoresis. The movement of molecules through the supporting medium is 
inversely proportional to the density of the medium. There are a number of supporting 
mediums commonly used for gel electrophoresis agar, agarose, polyacrylamide, 
starch etc. When choosing a support medium one must take into account its physical 
characteristic such as pore size and chemical composition. Molecules can interact 
and weakly bind to the supporting mediums charged groups affecting both migration 
and separation of molecules in gel electrophoresis. For the purpose of 
immunoelectrophoresis agarose is considered a better medium than Agar (Crowle, 
1973). Also the charged groups of the supporting medium can cause the phenomena 
endosmosis that impedes molecule migration. 
 
1.7.3 Endosmotic Flow 
During electrophoresis as ions move either towards the cathode or anode they drag 
along molecules of water with them. In a basic or neutral buffer the negatively 
charged groups of the supporting medium such as carboxylic groups in starch and 
agarose, sulfonic groups in agarose, silicon oxide on glass surfaces are fixed in place 
and thus cannot move towards the cathode (Westermeier, 2001). However their 
positively charged counter-ion can move towards the cathode. This results in a net 
migration or flow of water towards the cathodic side of gel. This flow of water carries 
carries neutrally charged solubilised substances along with it. 
 
The endosmotic flow is also known as electroendosmosis and the flow of water 
towards the cathode physically impedes the migration of negatively charged particles 
migrating to the anode. In addition buffer leaves the strip or gel support faster than it 
can re-enter at the anode side. This results in a drying on the cathodic side and in gel 
electrophoresis a thinning of the gel (Arquembourg, 1975). Increasing buffer 
conductivity increases the strength of the endosmotic flow and thus often a buffer of 
lower ionic strength is used to prevent endosmostic flow and increase migration 
speed at the expense of gel resolution (Arquembourg, 1975; Verbruggen, 1975). 
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1.7.4 Immunoelectrophoresis 
Immunoelectrophoresis is the name given to a group of techniques by which gel 
electrophoresis is used to force together antibody and antigen in order accelerate 
antibody-antigen precipitation and allow greater separation of serum components 
than other immunodiffusion tests (Crowle, 1973). The first immunoelectrophoretic 
technique was developed by Pierre Grabar at the Pasteur Institute of Paris. Unable to 
differentiate by double immunodiffusion a series of concentrated precipitin bands that 
were produced when examining a complex mixture of antigens, Grabar submitted the 
antigen mixture to electrophoresis before carrying out the double immune diffusion 
reaction. This separated the complex series of bands into a set of independent 
double diffusion reactions at locations imposed by ionization characteristics of 
antigens (Arquembourg, 1975). 
 
The rate at which antigen and antibody collide in immunoelectrophoresis is greater 
than during immunodiffusion. The time necessary for the primary reaction between 
antibody and antigen to develop during immunoelectrophoresis tests is comparable 
to that of immunodiffusion tests: however, the time necessary for a secondary 
reactions that lead to lattice formation, complex aggregation, and finally precipitation 
is not always sufficient, and results in antigen and antibody passing right through 
each other (Crowle, 1973).  
 
1.7.5 Buffer 
The effects of constituents of the buffer used for CIE are critical as they modulate the 
electrochemical properties of the reactants and conditions of the assay itself. In terms 
of the ionic strength of the buffer it was previously explained that by lowering it 
temperature is lowered, and fraction migration is increased due to a reduction in 
endosmotic flow.  
 
However lowering ionic strength also lowers electrophoretic resolution as high ionic 
strength buffer minimizes interactions between the migrating fractions and the 
supporting medium (Crowle, 1973). It must also be pointed out in order to lower 
conductivity of the buffer one must reduce the concentration of its constituent 
buffering molecules thus reducing the buffering capacity of the buffer. If buffering 
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capacity is not sufficient electrophoretic migration of H+ and OH- ions can result in 
changes in pH primarily at the termini of the medium that result in negative effects. 
For CIE to work the pH, is critical as it dictates the electrophoretic charge of the 
migrating fractions. The buffer pH needs to be alkaline enough that the net charge of 
the antigen becomes electronegative and the net charge of the antibody sera is 
neutral. However like all components there is an effective range of buffer ph; if the pH 
is too high it inhibits the precipitin reaction (Verbruggen, 1975).  
 
Commonly used buffer conditions are an ionic strength between 0.02-0.1 M although 
calculated ionic strength frequently agrees with what is actually determined by 
electrical conductance (Crowle, 1973) and the most commonly used pH for CIE is 
between 8.4-8.6 (Arquembourg, 1975; Axelsen, 1973; Crowle, 1973). Also Calcium-
lactate is often added as its addition results in a higher resolution and clearer band 
precipitation most likely due to the affinity of many proteins for bi-valent cations such 
as Ca2+ and Mg2+ (Anhalt & Yu, 1975; Axelsen, 1973; Verbruggen, 1975). In fact a 
Tris-tricine based buffer containing Ca-lactate has been shown to work well for CIE 
(Anhalt & Yu, 1975). 
 
1.8 Modifying ENA antigens for CIE 
Traditionally in a CIE assay there is a staining and wash step to improve perception 
of the precipitin bands. These steps are both a time consuming and labour intensive 
component of the CIE assay. A novel method to decrease the time required to reach 
assay completion is to modify specific antigens to fluoresce under a light source. This 
removes the need to wash and stain the gel achieving the goal of reducing the time 
required to reach assay completion.  A fluorescent dye can be covalently linked to an 
antigen using one of the commercially available amine reactive dyes. The amine 
reactive dyes contain a N-hydroxysuccinimide (NHS) ester that undergo a 
substitution reaction with the amines at the N-terminals and lysine side chains to form 
an amide bond between the fluorophore of the dye and the protein. This allows real-
time observation of the precipitin reaction upon excitation of the fluorophore.  
 
The modification of antigens proposes several problems. The site at which the 
fluorophore binds to the antigen may be the same as an antibody binding-site, or if 
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the location the fluorophore binds is close to that of an antibody binding-site it may 
physical block the antibody from accessing the binding site. If either of these events 
occur the antigenicity of the antigen will be reduced. Use of a modified antigen with 
reduced antigenicity will result in decreased assay sensitivity and will make the 
modified antigen unsuitable for use in a clinical diagnostic assay. Alternatively, it is 
possible that binding of the fluorophore to the antigen may increase antigenicity as 
antibodies may interact with the fluorophore either specifically (binding to the 
fluorophore) or non-specifically (fluorophore stabilises a weak Ag-Ab interaction). If 
the antigenicity is increased it will alter the specificity of the assay result and again 
make the modified antigen unsuitable for use in a clinical diagnostic assay. 
 
1.8.1 Modification of ENA antigens with Alexa Fluor® 488 amine reactive dye 
An internal study performed by Arotec Diagnostics (results unpublished) examined 
the possibility of using fluorophore-labelled ENAs to improve the CIE and DID assay 
methodology for diagnostic testing. In this study the ENAs were labelled with the 
Alexa-Fluor® 488 (AF488) amine reactive dye from Invitrogen. The results of this 
study demonstrated that labelling did not change the chemical properties of the 
antigen and that the CIE and DID assay methodology for diagnostic testing could be 
improved by using labelled-ENAs (results not shown). However, the cost of licensing 
the AF488 dye from Invitrogen restricted the commercial feasibility of using labelled-
ENAs in CIE and DID diagnostic tests. The Dylight 488 (D488) amine reactive dye 
from Pierce has been identified as an alternative to AF488 for the labelling of ENA 
antigens.  
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1.9 Aims 
The aims of this project are as follows 
 
1. To develop and optimise a novel CIE assay for the detection of ENA 
autoantibodies. This is includes comparison and selection one of two amine 
reactive dyes; Alexa Fluor® 488 (Invitrogen) or Dylight 488 (Pierce). The CIE 
assay conditions to be optimised include; gel composition, buffer composition, 
antigen concentration, and the running time of the assay. 
 
2. To evaluate clinically, the optimised novel CIE assay, and an in-house ELISA 
with a set of patient plasma samples sourced from the Wellington Hospital 
Immunology Department serum bank and four ENAs SSA, SSB, RNP/Sm, and 
Sm. 
 
3. To evaluate the effectiveness of the CIE assay compared to that of the ELISA 
using statistical analysis. 
 
4. To examine this data and provide a critical analysis of the clinical utility of the 
novel CIE assay for each respective ENA antigen examined. 
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2. Materials and Methods 
2.1 Antigen and Anti-sera 
All antigens SSA, SSB, RNP/Sm, Sm, Scl-70, and Jo-1 were derived from bovine 
thymus and produced by Arotec Diagnostics (www.arodia.com); Antigen catalogue 
numbers SSA #ATR02-02, SSB #ATL01-02, RNP/Sm #ATR01-02, Sm #ATS02-02, 
Scl70 #ATS01-02, and Jo-1 #ATJ01-02. The anti-RNP sera and anti-SSA/SSB sera 
used as both positive and negative controls were sourced from The Binding Site 
(www.bindingsite.com). The anti-Sm, anti Jo-1, and anti-Scl-70 were Arotec 
Diagnostics internal standards. Patient serum samples used to validate assay 
specificity were sourced from Wellington Hospital Immunology Department sera 
bank. 
2.2 Preparation and Labelling of Protein with 
Dylight-488 Fluor 
Antigen samples for labelling were thawed and dialysed overnight in carbonate 
coupling buffer (0.1 M carbonate, 0.4 M NaCl, pH 8.8). The protein concentration was 
determined using a BCA protein assay kit (Pierce). 
For protein labelling 1 mg of Dylight 488 (D488) amine-reactive dye (Pierce) was 
solubilised in 200 µL dimethylformamide and then added to the protein sample, and 
mixed well by vortexing. The reaction proceeded in the dark at room temperature 
(RT). The reaction was stopped by adding 1 ml of 1 M Tris-HCl, pH 8.0. The excess 
D488 was removed using a PD-10 desalting column (GE Life Sciences) according to 
the Manufacturer’s instructions. The wash buffer used was 20 mM Tris HCl, (pH 7.5), 
0.4 M NaCl, 3.5 mM MgCl2. 
2.3 Antigenicity of Labelled vs Unlabelled Proteins 
The antigens SSA, SSB, RNP/Sm, Sm, Jo-1, and Scl-70 were labelled with D488 
fluor at ratios (protein:fluor) of  640:1, 320:1, 160:1, 80:1, 40:1, 20:1, 10:1, and 5:1. 
The D488-labelled proteins were examined by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) visualised with using blue light 
excitation using a Invitrogen Safe ImagerTM transilluminator, and the image captured 
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using a Gel DocTM XR (Bio-Rad). The gels were fixed and stained with Coomassie 
blue and an image taken using white light transillumination in the Gel DocTM XR (Bio-
Rad). Images were analysed using Quantity One 1-D (Bio-Rad) software.  
Duplicates of SDS-PAGE gels were also examined by Western blotting. Gel proteins 
were transferred to nitrocellulose and placed into Western blot blocking buffer (10 
mM phosphate, (pH 7.4), 0.15 M NaCl, 0.02% w/v Tween 20, 0.5% w/v bovine serum 
albumin (BSA), 0.1% w/v Bronidox L) for 1 h. The blocking buffer was poured off and 
6 ml Western blot antibody dilution buffer (10 mM phosphate (pH 7.4), 0.15 M NaCl, 
0.02% w/v Tween 20, 1% w/v sodium caseinate, 0.1% w/v Bronidox L) was added. 
For each respective antigen 20 µl of its corresponding anti-sera was pipetted into the 
Western blot antibody dilution buffer to give a sera dilution of 1:300. Blots were 
rocked overnight at RT. The nitrocellulose blots were washed 3 times in phosphate 
buffered saline solution with Tween 20 (PBST) wash buffer (10 mM phosphate (pH 
7.4), 0.15 M NaCl, 0.02% w/v Tween 20, 0.1% w/v Bronidox L). Anti-human alkaline-
phosphatase antibody conjugate (Jackson) was diluted 1:6000 in Western blot 
antibody dilution buffer and 6 ml pipetted onto each blot. Blots were incubated for 1 h 
at RT.  Blots were washed 3 times in PBST wash buffer. The blots were developed in 
5 ml alkaline phosphatase development buffer (50 mM Tris-HCL (pH 9.0), 100 mM 
NaCl, 5 mM MgCl2) and 50 µl alkaline phosphatase substrate (25 mM nitro-blue 
tetrazolium chloride, 22 mM 5-bromo-4-chloro-3'-indolyphosphate p-toluidine salt, 
70% w/v dimethyl sulfoxide). The reaction was stopped by washing blots with de-
ionised H2O. Images were taken using the Gel DocTM XR (Bio-rad). 
Both unlabelled and D488-labelled antigens labelled at a ratio of 5:1 were analysed 
by enzyme linked immunoabsorbant assay (ELISA). For each antigen two ELISA 
assays were performed at two different antigen coating concentrations. For each 96-
well NUNC Maxisorp ELISA plate, half (48 wells) was coated with 0.1 ml unlabelled 
antigen in coating buffer (20 mM Tris-HCl, (pH 8.0), 0.15 M NaCl) and the other half 
coated with its equivalent D488-labelled antigen. The two plating concentrations for 
SSA were 1 µg/ml and 0.5 µg/ml; for SSB 0.5 µg/ml and 0.25 µg/ml; for RNP/Sm 0.5 
µg/ml and 0.25 µg/ml; for Sm 0.5 µg/ml and 0.25 µg/ml. Plates were blocked for 3 h 
at RT with coating buffer, containing 0.1% w/v BSA. The ELISA plates were washed 
3 times with wash buffer (20 mM Tris-HCl, (pH 7.5), 0.3 M NaCl, 0.1% Tween 20). 
Then each half plate was then incubated with 23 antigen positive sera samples (0.1 
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ml) and 1 negative control in duplicate (0.1 ml), both at a 1:100 dilution in antibody 
dilution buffer (20 mM Tris-HCl, (pH 7.5), 0.3M NaCl, 0.1% Tween 20, 0.1% w/v BSA, 
and 0.1% sodium caseinate). The ELISA plates were left at RT for 1 h and then 
washed 3 times with wash buffer. Then 0.1 ml of horse radish peroxidase-conjugated 
goat anti-human IgG (Jackson ImmunoResearch Laboratories) at 1:30,000 dilution in 
antibody dilution buffer was added per well and incubated for 1 h at RT. Plates were 
washed 3 times in wash buffer and developed in 0.15 ml of developer solution (0.1 M 
sodium acetate, (pH 5.5), 0.0125% w/v tetramethylbenzidine, 0.03% w/v hydrogen 
peroxide). The reaction was stopped by the addition of 50 µl of 2 M H2SO4 per well. 
Plates were read at 450 nm using a Biotek Powerwave 340 plate reader.   
2.4 Fluorecent Intensity of Labelled Protein 
Two fold serial dilutions were prepared (range 0.0313 µg, 0.0625 µg, 0.125 µg, 0.25 
µg, 0.5 µg, 1.0 µg, and 2.0 µg) of the proteins SSA, and RNP/Sm labelled with D488 
at a 5:1 ratio and examined by SDS-PAGE. The gel was viewed through an amber 
filter using blue light excitation using a Invitrogen Safe ImagerTM transilluminator, and 
the image captured using a Gel DocTM XR (Bio-Rad). The gels were then fixed and 
stained with Coomassie blue and an image taken using white light transillumination in 
the Gel DocTM XR (Bio-Rad). Images were analysed using Quantity One 1-D (Bio-
Rad) software.  
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2.5 CIE Apparatus modifications and configurations 
 A number of prototypes of the CIE apparatus were trialled: 
 
2.5.1 Apparatus 1 
An Amersham Biosciences powerpack connected to the modified insert of the 
Invitrogen iBaseTM illuminator by two lead cables. Electrophoresis with apparatus 1 
uses constant current and variable voltage.   
 
Figure 2 Apparatus 1 - cover on 
 
Figure 3 Apparatus 1 - cover off 
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2.5.2 Apparatus 2 (modified ibase) 
The modified insert in apparatus 1 was inserted into a modified iBaseTM unit that has 
an external resistor that can be used to restrict current.  Electrophoresis with 
apparatus 2 uses variable current at constant voltage.  
 
Figure 4 Apparatus 2 
2.5.3 Apparatus 3 (unmodified ibase) 
An unmodified ibase unit was used in conjunction with a modified iBaseTM insert that 
had an internal resistor to restrict current to 5 mA. Electrophoresis with apparatus 3 
uses variable current at constant voltage.  
 
Figure 5 Apparatus 3 inside Gel Doc XR 
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2.6 Comparison of Dylight 488 vs Alexa Fluor® 488 
 
2.6.1 Preparation and labelling of protein with Alexa Fluor® 488 
Preparation of and labelling of the antigens SSA, SSB, RNP/Sm, and Sm with Alexa 
Fluor® 488 (Invitrogen) was performed by a colleague as per the Manufacturer’s 
instructions. Protein concentration was determined using a BCA protein assay kit 
(Pierce). 
 
2.6.2 Comparison of fluorescent intensity D488 vs AF488 
The D488-labelled and AF488-labelled antigens (SSA, SSB, RNP/Sm, and Sm) were 
examined by SDS-PAGE. The gels were visualised using blue light excitation using a 
Invitrogen Safe ImagerTM transilluminator, and the image captured using a Gel DocTM 
XR (Bio-Rad). The same gels were fixed and stained with Coomassie blue and an 
image captured using white light transillumination in the Gel DocTM XR (Bio-Rad). 
Images were analysed using Quantity One 1-D (Bio-Rad) software.  
 
2.6.3 Comparison of D488 vs AF488 by CIE 
The D488-labelled and AF488-labelled antigens (SSA, SSB, RNP/Sm, and Sm) were 
examined by CIE. Each CIE assay was loaded in duplicate with a set of serum 
samples; one positive sera control, one negative sera control, and a clinical sample 
from the Wellington Hospital Immunology department. One set of sera was run 
against D488-labelled antigen and the other against AF488-labelled antigen. CIE 
assays were performed with Apparatus 3 and the standard CIE method (see below).   
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2.7 Optimisation of Counter Immunoelectrophoresis 
 
2.7.1 Standard Counter Immunoelectrophoresis Method 
A single agarose gel was placed onto the iBaseTM insert. A 2.5 x 35 x 30 mm (height-
depth-width) paper strip from Pall was placed on the iBaseTM insert overlapping the 
cathode terminal wire and the upper portion of the gel to act as a wick. A second wick 
of the same dimensions was placed on the iBaseTM insert overlapping the anode 
terminal wire and the lower portion of the gel (Fig. 6).  A 2.5 mL aliquot of buffer (see 
recipe below) was then pipetted onto each paper strip. Sera (10 µl) was then pipetted 
into each of lower wells (anodic side) of the gel. A pre-electrophoresis step was then 
performed by applying voltage to the gel before the addition of antigen for 5 min. 
After pre-electrophoresis, 5 µl of antigen was pipetted into the upper cathodic side 
wells of the gel. Electrophoresis was then performed on the gel until the assay 
endpoint was reached. The assay endpoint was determined to be the point the 
antigen in the negative control passes into the anodic antibody wells. The time 
required to reach the assay was antigen dependent. For SSA and SSB the time 
required was 30 min electrophoresis, Sm required 50 min, and RNP/Sm required 60 
min. Images of gels were acquired using the Gel DocTM XR (Bio-Rad). 
 
Figure 6 CIE Apparatus 2 cover off - Wick and gel placement 
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Figure 7 CIE Apparatus 2 cover on – assay running 
2.7.2 Agarose Gels 
High electro-endosmosis (HEEO) agarose (Roth) was dissolved in buffer (see recipe 
below) by heating in a microwave until it reached boiling point and then swirled gently 
until dissolved. Once dissolved, 2.5 mL of dissolved agarose solution was pipetted 
into a gel mould and a Gelbond® plastic film (Lonza) was placed over the surface of 
the mould. Gels were left at RT for 30 min to set. Each gel was then placed into a 
sealed plastic bag and stored at 4°C until use. 
 
2.7.3 Agarose concentration and Current 
Experiments were undertaken to determine the effect of agarose concentration, and 
the current applied during electrophoresis on CIE results.  
Using apparatus 1 CIE assays were run at constant current of 3 mA, 5mA, or 7 mA. 
Agarose gels were made at 0.4%, 0.6%, 0.8%, 1.0%, and 1.2% w/v agarose 
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concentrations in buffer (80 mM Tris, (pH 8.6), 24 mM Tricine). For each current, a 
gel was run at a different agarose concentration under the following conditions; 5 min 
pre-electrophoresis, and electrophoresis 60 min at 3 mA, 40 min at 5 mA, 20 min at 7 
mA, and contained SSA positive and negative control sera, and D488-labelled SSA 
antigen. 
2.7.4 Pre-electrophoresis time 
Using apparatus 1, two separate CIE assays were run with the positive and negative 
serum controls loaded at staggered time intervals of 5 min. For CIE assay 1, the time 
intervals were 5, 10, and 15 min pre-electrophoresis. For CIE assay 2, the time 
intervals were 0, 5, 10,15, and 20 min pre-electrophoresis. After the last pre-
electrophoresis interval D488 labelled SSA antigen was then loaded and the CIE 
assay run for another 40 min. 
2.8 Buffer 
 
2.8.1 Calcium lactate titration 
A series of CIE buffers were made (80 mM Tris, 24 mM Tricine, 0.05% w/v NaN3) 
with a titration (range 1 mM, 2 mM, 5 mM, 10 mM, 20 mM, and 40 mM) of Calcium-
lactate. Agarose gels (0.6% w/v) were made using each of the buffers. CIE assays of 
four 2-fold sera dilution series of the serum positive control, and a single serum 
negative control were performed under the following conditions; Apparatus 2, at 5 
mA, 5 min pre-electrophoresis, and 45 min electrophoresis.  
 38 
2.8.2 Buffer pH 
A range of buffers containing varying concentrations of Tris and Tricine, and a 
different pH were examined for their effect on CIE. Tris and Tricine concentrations 
were altered antagonistically in order to keep conductivity relatively the equal 
between buffers. 
 Buffer 1; 60 mM Tris, 32 mM Tricine, 5 mM Calcium-lactate, 0.05% w/v NaN3,  
  (pH 8.4), conductivity: 0.19 µM/s. 
 Buffer 2; 80 mM Tris, 28 mM Tricine, 5 mM Calcium-lactate, 0.05% w/v NaN3,  
  (pH 8.6), conductivity: 0.19 µM/s. 
 Buffer 3; 90 mM Tris, 20 mM Tricine, 5 mM Calcium-lactate, 0.05% w/v NaN3,  
  (pH 8.8), conductivity: 0.2 µM/s. 
The buffers were heated using a Heidolph Magnetic Stirrer MR Hei-Standard and the 
temperature and pH measured using the Orion 4 Star pH and conductivity meter. 
Agarose gels (0.6% w/v) were made using each of the buffers. CIE assays were 
performed using Apparatus 2, at 5 mA, with 5 min pre-electrophoresis, and 45 min 
electrophoresis. 
2.8.3 Tris-Tricine concentration 
Three buffers were made up with three different concentrations of Tris and Tricine. 
The ratio of Tris and Tricine were the same for each buffer to keep pH the same but 
altering conductivity between buffers. 
 Buffer 1A ; 45 mM Tris, 10 mM Tricine, 5 mM Ca-lactate, 0.05% w/v NaN3, 
  (pH 8.8), conductivity: 0.15 µM/s. 
 Buffer 2A ; 90 mM Tris, 20 mM Tricine, 5 mM Ca-lactate, 0.05% w/v NaN3,  
  (pH 8.8), conductivity: 0.2 µM/s. 
 Buffer 3A ; 180 mM Tris, 40 mM Tricine, 5 mM Ca-lactate, 0.05% w/v NaN3,  
  (pH 8.8), conductivity: 0.4 µM/s 
Agarose gels (0.6% w/v) were made and CIE assays performed under the following 
assay conditions; Apparatus 2, at 5 mA, as per the standard method. 
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2.9 Antigen Concentrations 
Serial 2-fold dilutions of the D488-labelled antigens SSA, SSB, RNP/Sm, and Sm 
were made (range 10 ng/µl to 80 ng/µl). A CIE assay was performed for each antigen 
with a positive sera control for each antigen concentration. Also a negative sera 
control was also run against 10 ng/µl and 80 ng/µl. Assay conditions used: Apparatus 
2 at 5 mA, and the standard CIE method. 
2.10 Antigen Concentration and Analytical 
Sensitivity 
Three 2-fold sera dilution series (range 1/2 to 1/256) were created using SSA/SSB, 
RNP/Sm, and Sm positive sera and unreactive sera. Using the respective dilution 
series 3 sets of CIE assays were performed using SSA antigen at concentrations 10, 
20, and 40 ng/µl. Using the respective dilution series, 2 sets of CIE assays were 
performed for the SSB, RNP/Sm and Sm antigens at concentrations of 20, and 40 
ng/µl. All CIE assays were performed using Apparatus 3 and the standard CIE 
method. 
2.11 Analytical Specificity 
Tests were undertaken to examine the analytical specificity of the method. Four CIE 
assays were performed, each with a different D488-labelled antigen (SSA, SSB, 
RNP/Sm, or Sm). For each assay the following 6 positive control sera samples were 
run for SSA, SSA/SSB, RNP, Sm, Jo-1, and Scl-70 and performed using Apparatus 3 
and the standard CIE method. 
 
2.12 CIE Time Series 
Tests were undertaken to determine the optimum length of time for a differential 
positive CIE test for each antigen. The end point of the assay (assay completion) is 
when the antigen runs through the gel past the negative control sera well. SSA, SSB, 
RNP/Sm, and Sm were run against their respective positive sera control, a negative 
sera control, and a buffer blank.  Assays were performed using Apparatus 3 and the 
standard CIE method. Apparatus 3 was placed inside the Gel DocTM XR (Bio-Rad) 
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during the run. Blue-light excitation from the iBaseTM (Invitrogen) was used to capture 
images periodically throughout each run without stopping the run.  
 
2.13 Clinical Validation of CIE Assays 
For each of the following antigens SSA, SSB, RNP/Sm, and Sm CIE and ELISA 
assays were performed using 281 ANA IIF positive clinical patient serum samples 
sourced from the Wellington Hospital Immunology Department serum bank. 
Our methods for review of the clinical data were forwarded to the Central Regional 
Ethics Committee who advised formal ethical approval was not required under two 
exemptions of the Ethical Guidelines for Observational Studies: Observational 
Research, Audits and Related Activities, NEAC, December 2006. No further review 
was required.  
 
2.13.1 CIE assay 
Each CIE assay was run with a positive and negative control serum, and four patient 
sera samples. Where less than four patient sera samples were run, buffer was 
loaded into the serum well instead. CIE assays were scored with a 0, 1, or 2 at the 
endpoint of the assay; 0 conclusive negative result; 1 inconclusive result; 2 positive 
result with clear precipitation reaction. Results were re-scored by a colleague familiar 
with the CIE assay, who was blinded to the sample identity to confirm results.   
For the purpose of CIE evaluation scores 0 and 1 were considered to analytically 
negative and score 2 were analytically positive. CIE assays performed using 
apparatus 3 and the standard CIE method. 
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2.13.2 ELISA assay 
The ELISA method was the same as previously described with the following 
modifications to the coating steps. A 96-well NUNC maxisorp ELISA plates was 
coated with 100 µl of each of the four antigens at a concentration of 1 µg/ml diluted in 
coating buffer. After blocking, each plate was incubated with 100 µl of the Wellington 
Hospital Immunology Department serum bank sera samples, 4 positive controls and 
1 negative control all diluted 1:100 in antigen dilution buffer.  
The endpoint of the ELISA assay was determined for each antigen (SSA, SSB, 
RNP/Sm, and Sm) using the formula and method described by Frey et al (1998). The 
ELISA was performed as previously described with the following modifications. Each 
of the four antigens was used to coat a quarter of a 96-well NUNC Maxisorp ELISA 
plate: plates were coated with 100 µl of antigen at a concentration of 1 µg/ml diluted 
in coating buffer. After blocking, each antigen sector was incubated with 100 µl from 
22 respective negative control sera (n = 22) and 1 positive control serum diluted 
1:100 in antigen dilution buffer, and also an antibody dilution buffer blank. The 
negative and positive control sera were Arotec internal standards. The t-value (t = 
2.518) was determined from a one-tailed t-distribution table with 99% confidence 
interval and 21 degrees of freedom. 
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2.13.3 Clinical data and classification 
Categorical clinical data was available for 156/281 serum samples. The categorical 
data came from a previous study (unpublished) performed at Wellington Hospital. 
Categorisation was performed by a clinical immunology registrar. Electronic patient 
records were used to assign categories based on the diagnostic criteria for Sjorgren’s 
syndrome and other anti-SSA associated diseases. Each serum sample was given a 
categorical score based on the following classifications. 
 
1. Primary Sjogren’s or subacute cutaneous / neonatal lupus  
2. Secondary Sjogren’s  
3. Probable Primary Sjogren’s or subacute cutaneous / neonatal lupus 
4. Probable Secondary Sjogren’s 
5. A definite connective tissue disease but no suggestion of Sjogren’s or 
subacute cutaneous / neonatal lupus 
6. Possible Sjogrens or connective tissue disease but information too limited 
7. Nil diagnoses and / or lack of evidence for any Sjogren’s, subacute 
cutaneous / neonatal lupus or other connective tissue disease 
 
2.13.4 Statistical methods 
Data was collated into 2 x 2 tables and Cohen’s kappa analysis was performed to 
compare the inter-rata agreement between the CIE and ELISA results. Area-
proportional Venn diagrams were generated the BIOINFOX Venn diagram program 
(http://bioinforx.com/lims/bxtoolbox/area-proportional-venn-diagram-plotter-editor-
data-extraction-overlapping) 
 
For the serum samples with categorical data available CIE and ELISA results were 
grouped together into case groups. Case group 1 (categorical groupings consistent 
with SS) consisted of samples categorised 1-4 (n = 24); Case group 2 (categorical 
grouping consistent with other CTD) consisted of samples categorised 5 and 6 (n = 
40); Case group 3 (control group) consisted of samples in category 7 (n = 92). Data 
was collated into 2 x 2 tables and the diagnostic sensitivity and specificity, as well as 
the likelihood ratios of the CIE and ELISA assays were calculated. 
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2.13.5 Western blot 
The clinical sera samples were examined by Western blot for each of the following 
antigens SSA, SSB, RNP/Sm, Sm. SDS-PAGE was performed with 2 µg protein per 
lane for each respective antigen and transferred to nitrocellulose by Western blot.  
The Western blot method and reagents were the same as previously described with 
the following modifications. The nitrocellulose blots were divided into strips and 
blocked individually with blocking buffer. Sera were diluted 1:100 in sera dilution 
buffer. Each strip was coated in 1 ml of a single sera dilution and incubated overnight 
at RT. Strips were washed 3 times in PBST wash buffer and coated in alkaline 
phosphatase conjugated anti-human IgG antibody diluted 1:6000 in antibody dilution 
buffer. Strips were incubated at RT for 1 h and then washed 3 times with PBST 
buffer. Strips were developed in 1 ml of alkaline phosphatase development buffer 
with 5 µl of substrate. The reaction was stopped by washing strips in deionized-H2O. 
 
Each blot was scored 0 for a negative result as compared to the negative control, 2 
for a positive result as compared to the positive control, or 1 for an inclusive result as 
compared to the positive and negative controls. 
 
2.14 Double Immunodiffusion 
Agarose gels (1 %) were made with high electro-endosmosis (HEEO) agarose 
(Roth). The agarose was dissolved in buffer (20 mM Tris HC, (pH 7.5), 0.4 M NaCl, 
3.5 mM MgCl2, 5 mM Calcium lactate) by heating in a microwave until it reached 
boiling point and then swirled gently until dissolved. Once dissolved 0.85 mL of 
dissolved agarose solution was pipetted into a gel mould and left to set for 1 hr at RT.  
Seven wells were then punched out of the agarose. 
 
Pipetted into the centre well, was 5 µl RNP/Sm antigen at a concentration of 50 ng/µl. 
This was allowed to diffuse for 10 min before the sera was pipetted into the 
surrounding wells. Into the surrounding wells 5 µl of sera was pipetted. Each gel was 
loaded with a positive and negative control serum, and four sera samples. In the case 
that less than four patient sera samples were run, buffer was loaded into the serum 
well instead. A strip of cellotape was placed over the gel to prevent evaporation of the 
gel. Gels were left in the dark at RT temperature overnight. The cellotape was 
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removed and the gels examined by blue light excitation using a Invitrogen Safe 
ImagerTM transilluminator, and the image captured using a Gel DocTM XR (Bio-Rad). 
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3 Results 
3.1 Preparation and Labelling of Protein with Dylight 488 Fluor 
The four antigens Scl-70, RNP/Sm, SSB, and SSA were incubated in series with the 
D488 and the labelling reaction stopped at different time intervals. The labelled 
antigens were examined by blue-light excitation. Fig. 8 shows as the reaction time 
increases so does the fluorescent intensity of the labelled antigen. For all four 
antigens there is no further increase in fluorescent intensity after 10 min reaction 
time. 
 
Figure 8 Dylight 488 labelling of ENA proteins reaction time 
Multiple samples of the SSA, SSB, RNP/Sm, Sm antigens were incubated with 
NHS ester Dylight 488 dye. Reactions were stopped at 0, 1, 5, 10, 15, 20, 30, 
60, 90, and 120 min. Samples were examined by SDS-PAGE and visualized 
through an amber filter with blue-light excitation. Reaction at 10 min highlighted 
in red. Banding patterns are typical for proteins examined by SDS-PAGE. 
Multiple bands are present due to dissociation of protein subunits. 
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3.2 Antigenicity of Labelled vs Unlabelled Protein 
 
The antigens Sm, RNP/Sm, Scl-70, Jo-1, SSA, and SSB were labelled with D488 at 
ratios (protein:fluor) of  640:1, 320:1, 160:1, 80:1, 40:1, 20:1, 10:1, and 5:1. Using the 
labelling series for each of the six antigens SDS-PAGE was performed and the gels 
examined by blue-light excitation, Coomassie staining, and Western blot (Fig. 9). As 
the labelling ratio increases from 640:1 to 5:1 a linear increase in fluorescent intensity 
was observed. The maximal fluorescent intensity achieved corresponded with the 
highest labelling ratio of 5:1, while no fluorescence was observed at a labelling ratio 
of 640:1. The Coomassie stained gels (Fig. 9) confirm the consistent loading of total 
protein per well. The western blots for each antigen show equal binding as the 
labelling ratio increases from 640:1 to 5:1 indicating that D488 does not prevent 
antibody binding on Western blot. 
 
Unlabelled and D488-labelled antigens (RNP/Sm, Sm, SSA, and SSB) labelled at a 
ratio of 5:1 were analysed by ELISA to determine whether the label disrupted 
antibody binding under native conditions. For each antigen two ELISA assays were 
performed at two different antigen coating concentrations. When the ELISA data of 
unlabeled and labelled protein was plotted against each other (Figs 10-13) and linear 
regression analysis performed, a linear relationship was observed between 
unlabelled and labelled antigens. Furthermore, for each plot the slope of the trend-
line tends towards 1, indicating that the label did not decrease or increase the ELISA 
score in a linear fashion. 
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Figure 9 Comparison of antigen labelling 
The antigens Sm, RNP/Sm, Scl-70, Jo-1, SSA, and SSB were labelled with 
D488 at ratios (protein:fluor) of  640:1, 320:1, 160:1, 80:1, 40:1, 20:1, 10:1, and 
5:1. Using the labelling series for each of the six antigens SDS-PAGE was 
performed and the gels examined by blue-light excitation (Fluor) using an amber 
filter, Coomassie staining, and Western blot.  
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Figure 10 Comparison of labelled & unlabelled SSA antigen by ELISA 
 
 
Figure 11 Comparison of labelled & unlabelled SSB antigen by ELISA 
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Figure 12 Comparison of labelled & unlabelled RNP/Sm antigen by ELISA 
 
 
Figure 13 Comparison of labelled & unlabelled Sm antigen by ELISA 
Figures 10-13 Comparison of labelled and unlabelled antigens by ELISA 
Unlabelled and D488-labelled antigens (RNP/Sm, Sm, SSA, and SSB) labelled 
at a ratio of 5:1 analysed by ELISA at two different antigen coating 
concentrations. The ELISA data of unlabeled and labelled antigens was plotted 
against each other and linear regression analysis performed. The values of the 
X & Y-axes are ELISA absorbances measured at 450 nm. 
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3.3 Fluorescent Intensity of D488-Labelled Proteins 
 
To determine the both the detection limit and level of fluorescent intensity relative to 
the mass of protein loaded into a gel 2-fold serial dilutions were prepared for the 
antigens (SSA, and RNP/Sm) labelled with D488 at a 5:1 ratio. These were examined 
by SDS-PAGE. The gel was viewed using blue light excitation through an amber 
filter. The gels were also stained with Coomassie blue and the images captured. The  
fluorescent and Coomassie images were compared. 
 
In figure 14 it can be seen that the relative fluorescent intensity increases relative to 
amount of protein loaded into the gel. This is true for both the antigens examined. 
Examining the fluorescent images (Fig 14) the limit of detection for SSA is 0.0613 μg 
and the limit of detection for RNP/Sm is 0.125 μg. Examining the Coomassie images 
the limit of detection for SSA is 0.5 μg and the limit of detection for RNP/Sm is 0.25 
μg.  
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Figure 14 Fluorescence vs Coomassie for D488-labelled antigens 
2-fold serial of the proteins SSA, SSB, RNP/Sm, and Sm labelled with D488 
examined by SDS-PAGE. The gel was viewed through an amber filter using blue 
light excitation using an Invitrogen Safe ImagerTM transilluminator, and the image 
captured using a Gel DocTM XR (Bio-Rad). The gels were then fixed and stained 
with Coomassie blue and an image taken using white light transillumination in the 
Gel DocTM XR (Bio-Rad). Images were analysed using Quantity One 1-D (Bio-
Rad) software.  
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3.4 Comparison of D488 and AF488 
3.4.1 Comparison of the relative fluorescent intensity of D488 and AF488 
labelled ENAs 
To examine whether there was any difference between D488 and AF488 labelled-
antigens (SSA, SSB, RNP/Sm, Sm) and their respective fluorescent intensities the 
D488-labelled and AF488-labelled antigens were examined by SDS-PAGE. The gels 
were visualised with using blue light excitation and relative fluorescent intensity of the 
bands quantified (Fig. 15-B, D, F, & H). The same gels were then fixed and stained 
with Coomassie blue and the relative signal intensity of the bands quantified (Fig. 15-
A, C, E, & G). Although the amount of protein loaded into each well was calculated to 
be 1 μg it can be observed by visual examination and by examining the relative 
signal intensities of the Coomassie gels of all the antigens, that quantity of AF488-
labelled antigens present is greater than that of the D488-labelled antigens. Despite 
this the relative fluorescent intensity of the D488 labelled antigens produces a 
stronger signal than the AF488 labelled antigens. This indicates that the proteins 
labelled with the D488 dye produce a stronger fluorescent signal those labelled with 
AF488. Examining the bands in the SSB and Sm Coomassie images, it can be 
observed that there is batch-batch variation of the protein subunits, between D488 
and AF488-labelled antigen samples. The quality control processes used to produce 
the antigen ensures that the antigen subunits are approximately the same between 
batches and that batch-batch variation is limited to the ratio of antigen subunits 
present in each sample. Thus batch-batch variation should not have an effect on the 
observations made regarding the differences in relative fluorescent intensity. 
 
3.4.2 Comparison of D488 and A488 by CIE 
To determine whether there was any difference between D488-labelled and AF488-
labelled antigens (SSA, SSB, RNP/Sm, and Sm) when used for CIE, three CIE 
assays were performed per antigen with different serum samples from the Wellington 
Hospital Immunology Department serum bank (Fig. 16). When a comparison was 
made between the precipitates of the SSA CIE assays the only observable difference 
was that the D488 precipitates were slightly brighter. When examining the images 
from the SSB CIE assays there was a difference in the precipitation pattern of the 
positive controls. The precipitate of the D488 positive control forms a wide spread arc 
and the precipitate of the AF488 positive control forms two distinct bands. However, 
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there appeared to be no difference in the appearance of the negative control or the 
patient sample. There were no noticeable differences between D488 and AF488 in 
any of the RNP/Sm CIE assays. In contrast the Sm CIE had significant differences 
between D488 and AF488 results. The D488 precipitates were brighter and better 
resolved than the AF488 precipitates, and the AF488 negative control had a high 
background noise. Representative images are shown in Fig 16. 
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Figure 15 Comparison of D488 and AF488 labelled antigens 
The D488-labelled and AF488-labelled antigens (SSA, SSB, RNP/Sm, and Sm) 
were examined by SDS-PAGE. The gels were visualised with using blue light 
excitation and relative fluorescent intensity of the bands quantitated (Fig. 15-B, D, 
F, & H). The gels were fixed and stained with coomasie blue and the relative 
signal intensity of the bands quantitated (Fig. 15-A, C, E, & G).  
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Figure 16 Comparison of D488 and AF488 by CIE 
Three CIE assays were performed per ENA each with a different serum sample. 
Each CIE assay was loaded in duplicate with a set of serum samples; one 
positive sera control (+), one negative sera control (-), and a clinical sample from 
the Wellington Hospital Immunology department (X). One serum set was run 
against D488-labelled antigen and the other against AF488-labelled antigen. 
CIE assays were performed with Apparatus 3 and the standard CIE method. In 
the Ag wells 1 µg antigen is loaded into all wells. Using an amber filter under 
blue light excitation the precipitin reaction can be observed as bright horizontal 
bands. 
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3.5 Optimisation of Counter Immunoelectrophoresis 
 
3.5.1 Agarose gel concentration and current 
To determine the effect of agarose concentration on the CIE assay, a series of 
replicate CIE assays were performed with increasing agarose concentrations. To 
examine the effect of electrical current applied during a CIE assay the agarose assay 
series was repeated twice again with two different applied currents. The results are 
shown in Fig. 17. As the agarose concentration increased the amount of background 
signal in the negative control increased (Fig. 17) without changing the resolution of 
the positive control. At the lowest agarose concentration (0.4 %) the gel would often 
deform when removed from the mold and be unusable for CIE. As the electrical 
current applied increased the length of time required for the assay to reach 
completion decreases (20 min decrease per 2mA increase) and altering the current 
had no effect on the resolution of the positive control. However, at 7 mA the gels heat 
increased resulting in deformation at the terminal ends of the gel. 
 
Figure 17 Optimisation of electrical current and agarose concentration 
CIE assays were run at constant current at either 3 mA, 5mA, or 7 mA. 
Agarose gels were made at 0.4%, 0.6%, 0.8%, 1.0%, and 1.2% w/v. For each 
current, a gel was run at a different agarose concentration with an SSA positive 
sera control, a negative sera control, and D488-labelled SSA antigen. In the Ag 
wells 1 µg antigen was loaded into all wells. Using an amber filter under blue 
light excitation the precipitin reaction was observed as bright horizontal bands. 
. 
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3.5.2 Pre-electrophoresis time 
To examine the optimal period of time required for pre-electrophoresis two assays 
were performed using different pre-electrophoresis times. As the pre-electrophoresis 
time period increased, the further away from the antibody well the precipitation 
reaction occurred (Fig. 18A). Furthermore, as the pre-electrophoresis time period 
increased, there was a slight increase in the background present in the negative 
control (Fig. 18B). The length of pre-electrophoresis time period appeared to have no 
effect on the resolution of the positive control. 
 
 
 
 
 
 
 
 
 
 
Figure 18 Pre-electrophoresis 
Pre-electophoresis was staggered in 5 min intervals. Positive 
sera control (+), negative sera control (-). In the Ag wells 1 µg 
antigen wass loaded into all wells. Using an amber filter under 
blue light excitation the precipitin reaction was observed as bright 
horizontal bands. 
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3.6 Optimisation of CIE Buffer 
 
3.6.1 Calcium-lactate titration 
To examine the effect of Calcium-lactate on CIE assay resolution, a series of gels 
were made with buffers that had a different Calcium-lactate concentration. Using 
these gels a series of replicate CIE assays were performed (Fig. 19) with the SSA 
antigen and its respective positive and negative control sera. As the Calcium-lactate 
concentration increased so did the resolution of the lower titer sera samples. 
However, as the Calcium-lactate concentration increased so did the time taken for 
the assay to reach completion, with the 40 mM calcium lactate assay unable to reach 
completion within 45 min. 
 
 
 
 
 
 
 
 
Figure 19 CIE buffer calcium lactate titration 
A series of replicate CIE assays, each performed with a different gel made 
at different calcium lactate concentrations (1 to 40 mM). 0.1 µg antigen 
was loaded into all Ag wells. A serum titration series was loaded into the 
Ab wells: 1 negative control; 2-5 2-fold sera dilution 1/16 to 1/2; 6 positive 
control. Using an amber filter under blue light excitation the precipitin 
reaction was observed as bright horizontal bands. 
 59 
3.6.2 Optimisation of buffer pH 
To examine the effect of buffer pH on CIE assay resolution, three buffers were made 
(Buffers 1-3 see materials & methods).  Each buffer was made with the same 
constituents although with different concentrations of Tris and Tricine. This gave 
buffers 1-3 a different pH (calculated to be pH 8.4, 8.6, and 8.8 respectively) but the 
same relative conductivity (0.19 - 0.2 µM/s).  Each buffer was heated between 15-
40°C and its pH measured (Fig. 20).  The change in pH as temperature increased 
was approximately linear. The difference in pH step-wise between the 3 buffers was 
approximately 0.2 pH units and the rate of pH change for each of the buffers was 
approximately the same.  
 
Three different CIE gels were made using each of the 3 buffers. These were used to 
run 3 replicate CIE assay using an SSB sera titration series (Fig. 21). When the 3 
images from the 3 assays were compared there was no difference in band resolution, 
completion time, or difference in the negative control background. 
 
 
 
 
 
 
Figure 20 Buffer pH vs Temperature 
Three buffers with identical constituents but at different concentrations were 
prepared. The pH of each buffer was measured while it was simultaneously 
being heated. The graph shows the change in pH as temperature increases 
for each of the three buffers.  
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3.6.3 Optimisation of buffer Tris-Tricine concentration 
To examine the effect of Tris-Tricine concentration, 3 buffers were made with 
increasing Tris-Tricine concentrations; Buffers 1A (45 mM Tris and 10 mM Tricine), 
2A (90 mM Tris and 20 mM Tricine), and 3A (180 mM Tris and 40 mM Tricine). Three 
different CIE gels were made using each of the 3 buffers. These were used to run 
replicate CIE assays using an SSA sera titration series (Fig. 22). As The Tris-Tricine 
concentration increased the resolution of the precipitin bands decreased. There was 
no change in the background of the negative control. Also gels made with Buffer 1A 
would sometimes deform during electrophoresis. 
 
Figure 21 The effect of buffer pH on CIE 
A series of replicate CIE assays, each performed with a different gel made with 
Buffers 1-3. In the Ag wells 0.1 µg SSB antigen was loaded into all wells. A 
serum titration series was loaded into the Ab wells: Lane1 negative control; 
Lanes 2-5 2-fold sera dilution 1/16 to 1/2;Lane 6 positive control. Using an 
amber filter under blue light excitation the precipitin reaction was observed as 
bright horizontal bands. 
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3.7 Antigen concentration 
 
3.7.1 Antigen titration 
To examine the optimal concentration of antigen required for CIE a 2-fold antigen 
titration series was created with range 80 ng/µl to 10 ng/µl for SSA, SSB, RNP/Sm, 
and Sm. CIE assays were performed with each titration series and their 
corresponding positive and negative control sera (Fig. 23). The following SSA antigen 
concentrations are suitable for CIE 10, 20, and 40 ng/µl as the band fluorescence 
was clearly visible and bands were clearly defined. For SSB, RNP/Sm, and Sm the 
antigen concentrations suitable for CIE are 20, and 40 ng/µl (Fig. 23).  
 
Figure 22 Optimisation of Tris-Tricine concentration 
A series of replicate CIE assays, each performed with a different gel made 
with Buffers 1A-3A. In the Ag wells 0.1 µg of the SSA antigen was loaded into 
all wells. A serum titration series was loaded into the Ab wells: Lane1 
negative control; Lanes 2-5 2-fold sera dilution 1/16 to 1/2; Lane 6 positive 
control. Using an amber filter under blue light excitation the precipitin reaction 
was observed as bright horizontal bands. 
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3.7.2 Antigen concentration vs sera titration series 
To examine the effect of antigen concentration on band resolution a 2-fold serum 
titration series was created (range 1/1 to 1/256) and this series was examined by CIE 
assay at each of the previously identified antigen concentrations (Figs 24-27). 
 
As antigen concentration increased so did the fluorescence intensity and 
consequently visibility of the bands. Fluorescence intensity and visibility is strongest 
at an antigen concentration of 40 ng/µl. At an SSA antigen concentration of 10 ng/µl 
the bands are noticeably less defined than at 20, and 40 ng/µl (Fig. 24). Likewise, for 
all the antigens, there is no difference in the definition of bands between 20, and 40 
ng/µl. Notably, the presence of a secondary band correlated with an increasing sera 
titer.  The limit of detection defined as a visible band clearly differentiable from the 
negative control for SSA, RNP/Sm, and Sm was at the 1/64 sera dilution. For SSB it 
was at the 1/4 sera dilution. 
Figure 23 CIE antigen titration 
A series of replicate CIE assays, each performed with a different a different 
antigen. An antigen titration series was loaded into the Ag wells: 10, 20, 40, & 80 
ng/μl. For each antigen a respective positive sera control (+), and negative sera 
control (-) was loaded into the Ab wells. Using an amber filter under blue light 
excitation the precipitin reaction was observed as bright horizontal bands. 
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Figure 24 SSA sera titrations 
 
 
Figure 25 SSB sera titrations 
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Figure 26 RNP/Sm sera titrations 
 
Figure 27 Sm sera titrations 
 
 
 
 
 
Figures 24-27 
Replicate CIE assays, each performed with a different antigen at different 
antigen concentrations: 10, 20, & 40ng/μl for SSA and 20, & 40ng/μl for SSB, 
RNP/Sm and Sm. In the Ag wells 5 µl antigen was loaded into each well. A 
serum titration series was loaded into the Ab wells; Lane1 negative control, 
Lanes 2-5 2-fold sera dilutions 1/256 to 1/32, Lane 6 positive control, Lane 7 
negative control, Lane 8-11 sera dilutions 1/16 to 1/2, Lane 12 positive 
control. Using an amber filter under blue light excitation the precipitin reaction 
was observed as bright horizontal bands. 
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3.8 Antigen Analytical Specificity 
To examine the analytical specificity of the antigens SSA, SSB, RNP/Sm, and Sm 
four CIE assays were performed with a single antigen and 6 different ENA reactive 
sera; anti-SSA, anti-SSA/SSB, anti-RNP, anti-Sm, anti-Jo-1, and anti-Scl-70 (Fig. 28). 
As expected, the SSA antigen reacted with the anti-SSA sera, and anti-SSA/SSB 
sera; the SSB antigen reacted with anti-SSB sera; the RNP/Sm antigen reacted with 
the anti-RNP, and anti-Sm sera; the Sm antigen reacted with the anti-Sm sera. There 
was no non-specific cross reactivity of the antigens detected. 
 
 
 
 
 
Figure 28 Antigen analytical specificity 
Four CIE assays were run each with a different antigen: 5 µl was 
loaded into each Ag well at an antigen concentration 10 ng/µl. The Ab 
wells were loaded with 6 different antigen specific sera: 10 µl was 
loaded into each well. Using an amber filter under blue light excitation 
the precipitin reaction was observed as bright horizontal bands. 
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3.9 Antigen Time Series 
CIE assays using the antigens SSA, SSB, RNP/Sm, and Sm were run against their 
respective positive sera control, a negative sera control, and a buffer blank. Images 
were taken periodically throughout the length of the assay (Figs 29 and 30). The 
presence of a defined precipitation band becomes observable after 12 min for all 
antigens. The end point of the assay is when the antigen runs through the gel past 
the negative control sera well. For the SSA and SSB antigens it took 30 min to reach 
the assay endpoint and for RNP/Sm and Sm it took 50 min to reach the assay 
endpoint. At the endpoint of the RNP/Sm assay there was low background 
fluorescence in the negative sera control lane that persisted
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Figure 29 SSA and SSB CIE time series 
A CIE assay was performed with two antigens (Lanes 1-3 SSA and Lanes 
4-6 SSB): 5 µl was loaded into each Ag well at an antigen concentration 10 
ng/µl. The Ab wells were loaded with 10µl: Lanes 1 & 5 positive control 
sera, Lanes 2 & 4 negative control sera, Lanes 3 & 6 buffer blank. Using an 
amber filter under blue light excitation the precipitin reaction was observed 
as bright horizontal bands. 
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Figure 30 RNP/Sm and Sm time series 
A CIE assay was performed with two antigens (Lanes 1-3 RNP/Sm and 
Lanes 4-6 Sm): 5 µl was loaded into each Ag well at an antigen concentration 
10 ng/µl. The Ab wells were loaded with 10 µl: Lanes 1 & 4 positive control 
sera, Lanes 2 & 5 negative control sera, Lanes 3 & 6 buffer blank. Using an 
amber filter under blue light excitation the precipitin reaction was observed as 
bright horizontal bands. 
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3.10 Clinical Validation of the CIE Assays 
To validate the CIE assays for the SSA, SSB, RNP/Sm, and Sm antigens CIE assays 
were performed using 281 clinical samples from the Wellington Hospital Immunology 
Department serum bank. The presence of a clearly defined precipitin band at the end 
point of the assay was scored as a positive CIE result. Results that did not produce a 
clearly defined precipitin band were scored as a negative CIE result.  
 
The 281 clinical samples were also examined by ELISA for each of the antigens 
SSA, SSB, RNP/Sm, and Sm. The detection cutoff for each specific antigen by ELISA 
was determined, by determining the 99% confidence interval of the mean ELISA 
score of a sample of negative controls (Frey et al., 1998). All true negative results are 
expected to lie within this interval. The upper confidence value of the mean is taken 
to be the ELISA cut off point. The ELISA endpoints for each respective antigen are 
summarised in Table 5. An ELISA score above the endpoint is considered positive 
and a ELISA score equal or below the endpoint is considered negative. 
 
Antigen	   ELISA	  Cutoff	  
SSA	   Negative	  ≤	  0.462	  <	  Positive	  
SSB	   Negative	  ≤	  0.369	  <	  Positive	  
RNP/Sm	   Negative	  ≤	  0.266	  <	  Positive	  
Sm	   Negative	  ≤	  0.280	  <	  Positive	  
	  	   	  	  
Table 5. Endpoint cutoffs for anti-ENA ELISAs 
 
3.10.1 Correlation between CIE and ELISA clinical samples scores 
Data was collated into 2 x 2 tables and Cohen’s kappa analysis was performed to 
compare the inter-rata agreement between the CIE and ELISA clinical sample results 
(Tables 6-9). To visualise the agreement between CIE and ELISA clinical sample 
positive results Venn diagrams were created (Fig. 31). The Cohen’s kappa (k) value 
for the inter-rata agreement between the SSA CIE and ELISA results was 0.89. This 
indicates a strong agreement between the observations of each assay. The k-values 
for the inter-rata agreement between the SSB, RNP/Sm, and Sm CIE and ELISA 
results were 0.48, 0.7, and 0.38 respectively and indicate a moderate, a substantial, 
and fair agreement between the observations, of each respective set of results.  
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Figure 31 Overlap between CIE and ELISA positive results 
Area-proportional Venn diagrams were generated the BIOINFOX 
Venn diagram program 
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SSA	   ELISA	  Positive	   ELISA	  Negative	   Total	  
CIE	  Positive	   82	   5	   87	  
CIE	  Negative	   8	   186	   194	  
Total	   90	   191	   281	  
	  	   	  	   	  	   	  	  
Cohen's	  kappa	   0.89	   	  	   	  	  
Table 6. Correlation between SSA CIE and ELISA clinical samples scores 
 
SSB	   ELISA	  Positive	   ELISA	  Negative	   Total	  
CIE	  Positive	   19	   0	   19	  
CIE	  Negative	   33	   229	   262	  
Total	   52	   229	   281	  
	   	   	   	  Cohen's	  kappa	   0.48	   	  	   	  	  
Table 7. Correlation between SSB CIE and ELISA clinical samples scores 
 
RNP/Sm	   ELISA	  Positive	   ELISA	  Negative	   Total	  
CIE	  Positive	   39	   14	   53	  
CIE	  Negative	   11	   217	   228	  
Total	   50	   231	   281	  
	   	   	   	  Cohen's	  kappa	   0.70	   	  	   	  	  
Table 8. Correlation between RNP/Sm CIE and ELISA clinical samples scores 
 
Sm	   ELISA	  Positive	   ELISA	  Negative	   Total	  
CIE	  Positive	   15	   0	   15	  
CIE	  Negative	   39	   227	   266	  
Total	   54	   227	   281	  
	   	   	   	  Cohen's	  kappa	   0.38	   	  	   	  	  
Table 9. Correlation between Sm CIE and ELISA clinical samples scores 
 
3.10.2 Correlation between clinical data and ELISA and CIE diagnostic assays 
Categorical clinical data was available for 156 of the 281 clinical sera samples tested.  
For the serum samples with categorical data available their corresponding CIE assay 
and ELISA results were grouped together into case groups. Case group 1 
(categorical groupings consistent with SS) consisted of samples categorised 1-4; 
Case group 2 (categorical grouping consistent with other CTD) consisted of samples 
categorised 5 and 6; Case group 3 (control group) consisted of samples in     
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category 7. The results of the clinical sera sample CIE assays and ELISAs in Case 
groups 1 and 2 were cross reference with the results in Case group 3 to determine 
the diagnostic specificity and sensitivity, PLR and NLR of the CIE assays and ELISAs 
(Tables 10 and 11).  
 
The performance characteristics of the ENA CIE assay and ELISA results assigned 
to Case group 1 were examined (Table 10). The diagnostic specificity of all CIE 
assays and ELISAs were greater than or equal to 85.9%. Furthermore, there was 
much more variation in the diagnostic sensitivity of the assays ranging between 
12.5%-70.8%. The specificity and the PLR of the SSA CIE assay were superior to 
that of the SSA ELISA. However, the sensitivity and NLR were approximately the 
same. The diagnostic specificity of the SSB CIE assay (98.9%) was superior to that 
of the ELISA (89.1%). The PLR of the SSB CIE assay was very high (15.33) 
compared not only with the SSB ELISA but with all other ENA CIE assays and 
ELISAs. The values for the SSB CIE diagnostic sensitivity and NLR were not as 
favorable (16.7% and 0.84 respectively) compared to the diagnostic sensitivity and 
NLR of the SSB ELISA (54.2% and 0.51%) respectively. The values for PLR, 
diagnostic sensitivity and specific were lower for the RNP/Sm CIE (3.51, 45.8%, and 
87.0% respectively) than the RNP/Sm ELISA (5.11, 50%, and 90.2% respectively). 
Also the NLR value was higher for the RNP/Sm CIE (0.62) than the RNP/Sm ELISA 
(0.55). The values for diagnostic specificity, PLR, and NLR were higher for the Sm 
CIE assay (97.8%, 5.75, and 0.89 respectively) than the Sm ELISA assay (85.9%, 
2.36, and 0.78 respectively). Notably, the PLR of the Sm CIE assay is approximately 
double that of the Sm ELISA. The diagnostic sensitivity of the Sm CIE assay (12.5%) 
is approximately a third that of the Sm ELISA (33.5%). 
 
The performance characteristics of the ENA CIE assay and ELISA results assigned 
to Case group 2, were examined (Table 11). The diagnostic specificities for all ENA 
CIE assays and ELISAs in this Case group 2 were the same as those in Case group 
1 analysis (Fig 10.) because the Control group (Case group 3) was the same for 
both. The diagnostic sensitivity of all assays was low ranging from (2.5%-22.5%). 
The values for PLR (range 0.92-3.45) and NLR (range 0.86-1.01) for all assays were 
poor.  
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Table	  10:	  Performance	  characteristics	  of	  CIE	  and	  ELISA	  against	  Case	  group	  1	  clinical	  
serum	  samples	  
	  	   Sensitivity	  	   Specificity	   PLR	   NLR	  
SSA	  CIE	   70.8%	   90.2%	   7.24	   0.32	  
SSA	  ELISA	   70.8%	   88.0%	   5.92	   0.33	  
	   	   	   	   	  SSB	  CIE	   16.7%	   98.9%	   15.33	   0.84	  
SSB	  ELISA	   54.2%	   89.1%	   4.98	   0.51	  
	   	   	   	   	  RNP/Sm	  CIE	   45.8%	   87.0%	   3.51	   0.62	  
RNP/Sm	  ELISA	   50.0%	   90.2%	   5.11	   0.55	  
	   	   	   	   	  Sm	  CIE	   12.5%	   97.8%	   5.75	   0.89	  
Sm	  ELISA	   33.3%	   85.9%	   2.36	   0.78	  
 
Table	  11:	  Performance	  characteristics	  of	  CIE	  and	  ELISA	  against	  Case	  group	  2	  clinical	  
serum	  samples	  
	  	   Sensitivity	  	   Specificity	   PLR	   NLR	  
SSA	  CIE	   22.5%	   90.2%	   2.30	   0.86	  
SSA	  ELISA	   22.5%	   88.0%	   1.88	   0.88	  
	   	   	   	   	  SSB	  CIE	   2.5%	   98.9%	   2.30	   0.99	  
SSB	  ELISA	   10.0%	   89.1%	   0.92	   1.01	  
	   	   	   	   	  RNP/Sm	  CIE	   22.5%	   87.0%	   1.73	   0.89	  
RNP/Sm	  ELISA	   17.5%	   90.2%	   1.79	   0.91	  
	   	   	   	   	  Sm	  CIE	   7.5%	   97.8%	   3.45	   0.95	  
Sm	  ELISA	   20.0%	   85.9%	   1.42	   0.93	  
 
 
 
 
 
 
3.10.3 Western blot 
After testing the clinical sera samples by CIE assay and ELISA was completed, when 
the results of the CIE assay and ELISA differed, a Western blotting was attempted as 
a differential test. The blots were scored 0 for a negative result as compared to the 
negative control, 2 for a positive result as compared to the positive control, or 1 for an 
inclusive result as compared to the positive and negative controls. During testing it 
was observed that a high proportion of the Western blots were producing 
Tables 10 & 11 
Using Case group 1 (Table 10) and Case group 2 (Table 11) clinical data 
the performance characteristics diagnostic sensitivity and specificity, 
positive likelihood ratio (PLR), and negative likelihood ratio (NLR) were 
determined for the each of the antigens (SSA, SSB, RNP/Sm, & Sm) with 
their respective CIE assay and ELISAs. 
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inconclusive results, with approximately half the samples tested scored as being 
inconclusive (See appendices for results). Therefore, further testing was stopped 
since the Western blot results were considered to be unusable for analysis because 
of the high proportion of inconclusive results, and the Western blotting method used 
was deemed to be insufficient as differential test.  
 
3.11 Double Immunodiffusion 
To determine the whether the D488-labelled RNP/Sm antigen would be suitable for 
DID a series of RNP/Sm double DID assays were performed. The serum samples 
used to examine the RNP/Sm DID assay were a selection of Wellington Hospital 
Immunology Department sera samples and selection of Arotec internal standards 
(Figs 32 & 33). Clinical samples that were positive by ELISA and CIE, produced a 
precipitin band. None of the samples that were negative by ELISA and CIE produced 
a precipitin band. Also all the Arotec internal standards that were tested produced 
results that were consistent with known specificity of the sera tested.  
 
 
Figure 32 RNP/Sm DID assays with patient serum samples 
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Figure 33 RNP/Sm DID assays with Arotec internal standards 
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To determine the analytical sensitivity of the RNP/Sm DID assay a serum titration 
series was examined (Fig. 34). The point at which precipitation became 
indistinguishable from the negative control occurs between 1/8 and 1/16 sera dilution.  
 
 
Figure 34 RNP/Sm DID assays with a serum titration series 
 
 
 
 
 
 
 
Figures 31-33 RNP/Sm DID assays 
Using an amber filter under blue light excitation the precipitin reaction 
was observed as a bright bands that occurred between the center well 
(containing the D488-labelled RNP/Sm antigen) and the numbered 
outer wells (containing different sera samples). 
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4. Discussion 
4.1 Labelling and comparison of D488 vs AF488 
The overall objective of this study was to develop and validate a novel CIE assay for 
the detection of ANAs using fluorescent ENAs. The first objective of this study was to 
compare the two amine reactive dyes Alexa Fluor® 488 and Dylight 488. To begin 
the method used to label antigens with D488 was examined. The complexity of the 
method and time required to optimally label antigens with D488 was comparable to 
the method and time required to label proteins with AF488.  
 
Antigens labelled with D488 were suitable for use in diagnostic testing by CIE. A 
change in antibody binding caused by the labelling of an antigen with D488, would 
invalidate the use of said D488-labelled antigens if used for diagnostic testing by CIE. 
Therefore, the Western blot patterns of D488-labelled antigens (SSA, SSB, RNP/Sm, 
Sm, Jo-1, & Scl-70) were examined. If labelling affected antibody binding, then as the 
level of D488 labelling increased, an altered pattern of antibody binding would be 
expected. Furthermore, this altered pattern would be exacerbated as the level of 
D488 bound to the antigen increased. There was no observable change in Western 
blot pattern when the antigens were labelled with D488. The ELISA absorbances’ of 
unlabelled and labelled antigens (SSA, SSB, RNP/Sm, & Sm) were also compared. 
These data indicate that there is no alteration of antibody binding caused by D488-
labelling.  
 
The level of fluorescence produced from the D488-labelled antigens was sufficient for 
detection by the human eye and thus sufficient as an alternative to staining for the 
visualization of antigens. When the D488-labelled antigens (SSA, and RNP/Sm) are 
examined by SDS-PAGE and viewed by blue light excitation through an amber filter 
the smallest amount of protein visible by the human eye was 0.125 µg for RNP/Sm, 
and 0.0625 µg for SSA. However, when the same gels are fixed and stained with 
Coomassie blue the smallest amount of protein visible was 0.25 µg for RNP/Sm, and 
0.5 µg for SSA. These results indicate that using D488-labelled proteins for CIE will 
not only decrease the time required for visualisation the antigen present in a gel (by 
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removal of the staining step) but that visualisation of the antigen may also be 
improved.  
 
D488 is superior to AF88 for the labelling of antigens. When the fluorescent intensity 
of D488-labelled antigens (SSA, SSB, RNP/Sm, & Sm) was compared with the 
fluorescent intensity of AF488-labelled antigens the relative signal intensity produced 
by the D488-labelled antigens was superior to the signal intensity of the AF488-
labelled antigens. Also when comparing the precipitation patterns of D488-labelled 
and AF488-labelled antigens by CIE it was observed that D488 produced brighter 
bands and the observed resolution of precipitin bands using D488-labelled Sm was 
superior to that of AF488-labelled Sm. 
 
4.1 Optimisation of the ENA CIE assays 
After selection of D488 as the labelling fluor, optimisation of the CIE began with the 
evaluation of the agarose concentration and electric current applied during 
electrophoresis. These two parameters determine the speed at which the molecular 
components migrate through the gel and thus the overall time taken to reach assay 
completion. As the CIE assay was intended for use as a diagnostic tool the less time 
required to reach assay completion the better. Lowering the agarose concentration 
while inversely increasing the applied electric current decreased the time necessary 
to reach assay completion. However at an agarose concentration, of 0.4% (w/v) the 
gel became unstable, and once the current, exceeded 5 mA the gel would begin to 
deform during the CIE. Thus the optimal conditions were determined; agarose 
concentration 0.6% (w/v) and 5 mA applied current. 
 
The novel CIE method contains a pre-electrophoresis step where serum is loaded 
onto the CIE gel and run prior to the addition of the antigen. A pre-electrophoresis 
step was thought to be necessary as the serum migrates relatively slowly (compared 
to the antigen) as its pulled along by endosmosis, and thus the position in the gel that 
precipitation occurs may be too close to the serum well for sufficient 
resolution/differentiation of a result. Pre-electrophoresis was examined and the 
optimal length of time for pre-electrophoresis was determined to be 5 min. 
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The buffer used for CIE is critical as it affects the electrical properties of the medium, 
the electrochemical properties of the molecules (serum proteins and antigens), and 
also influences the ability of the molecules to precipitate. It was identified in the 
literature that tris and tricine were suitable buffering components for CIE, and the 
addition of sodium-azide was also commonly added to prevent bacterial growth in the 
buffer/gel (Axelsen et al, 1973). As Ca-lactate was said to increase the resolution of 
precipitin bands, Ca-lactate was added, and its concentration optimised (Axelsen et 
al, 1973).. It was at this point that it was noticed that the buffer pH was susceptible to 
temperature induced changes. Three different buffers each with a different pH (8.4, 
8.6, & 8.8 at RT) were produced (Buffer 1-3), by altering the relative ratios of Tris and 
Tricine. The combined concentration of Tris and Tricine were approximately the same 
in order to keep the conductivity approximately the same. The change in pH of each 
buffers as temperature increased was examined, and the effect of each buffer on the 
CIE assay resolution was also examined. The rate of pH change for each of the 
buffers was approximately the same and there was no observable difference in CIE 
assay resolution between the buffers. The temperature of a CIE gel during an assay 
run is approximately on average 30°C and thus Buffer 3 (pH 8.8 at RT) was 
determined to be optimal as at this temperature it has a pH of 8.5, and the optimal pH 
of a CIE assay is said to be between 8.4-8.6 (Arquembourg, 1975; Axelsen, 1973; 
Crowle, 1973). The optimal concentration of Tris and Tricine was determined to be 90 
and 20 mM respectively. 
 
The optimal amount of antigen loaded during the SSA, SSB, RNP/Sm, and Sm CIE 
assay is 0.1µg (5 µl at 20 ng/µl). Less than this there is a loss of precipitin band 
resolution, and using antigen load greater than this provides no observable benefit in 
precipitin band resolution. 
 
The analytical sensitivity for the SSA, SSB, RNP/Sm, and Sm CIE assays was 
examined. The limit of detection for the SSA, RNP/Sm and Sm assays occurred at a 
1/64 dilution in sera, and 1/4 dilution in sera for SSB. This difference in sensitivity of 
the SSB assay compared to the other ENA antigens was expected as a significant 
proportion of anti-SSB antibodies are known to be non-precipitating (Beer et al., 
1996). Furthermore, anti-idiotypic antibodies present in patient serum have been 
shown to block binding of anti-SSB antibodies to SSB antigen peptides (Routsias et 
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al., 2002). The analytical specificity of the CIE assays was examined and the ENAs 
were determined to be specific for the respective anti-sera.  
 
The use of D488-labelled antigens in CIE allows for the rapid screening of patient 
sera for ANAs. The endpoint of the CIE assays was determined to be 30, 30, 50, and 
60 min for SSA, SSB, Sm, and RNP/Sm respectively. Although, for the RNP/Sm CIE 
assay a low fluorescent background was left in the negative control lane once the 
assay had reached its endpoint. This is likely due to non-specific interactions 
between the agarose and the RNP antigen that prevent the total migration of the 
antigen. This background may make differentiation between the negative control and 
a low titer test sample difficult. Furthermore, for the correct interpretation of result the 
assay run-time used must be followed stringently as some samples tested produced 
a clearly positive precipitin band that would migrate towards the cathodic well. If the 
endpoint run-time was exceeded the positive precipitin band would migrate past 
cathodic antigen wells producing what would appear to be a negative result (thus a 
false negative). See appendix 1 for further results and discussion. 
 
4.2 Clinical Evaluation of the ENA CIE assays 
The clinical utility of the novel anti-ENA SSA, SSB, RNP/Sm, and SM CIE assays 
were evaluated using a set of 281 patient serum samples sourced from the 
Wellington Hospital Immunology Department serum bank, and the results compared 
to those of an in house ELISA. Statistical analysis using Cohen’s kappa statistic was 
performed to examine how closely the results between CIE assays and their 
respective ELISAs agreed with each other. The kappa statistic that tends towards 1 
shows a stronger agreement and for SSA, SSB, RNP/Sm, and Sm the kappa were 
0.89, 0.48, 0.7, and 0.38 respectively. The strong agreement between the SSA CIE 
assay and ELISA indicate that one assay could be switched for another and one 
would get similar levels of detection. The kappa statistics for SSB and Sm indicate 
that there is significant difference between the CIE assay and ELISA results and that 
the CIE assay and ELISA could not be switched without a change in the levels of 
detection.  Although the kappa for RNP/Sm is considered substantial it is not high 
enough to indicate conclusively that there is not a significant difference between the 
CIE assay and ELISA results. Phan et al (2001) calculated the kappa statistic for CIE 
vs ELISA for the following antigens SSA, SSB, and RNP/Sm. The values of which 
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were 0.44, 0.5, and 0.42 for SSA, SSB, and RNP/Sm respectively. The agreement 
(kappa) between the novel CIE assay and ELISA for SSA, and RNP/Sm is stronger 
than the agreement reported by Phan et al.  
 
Categorical clinical data was available for 156 of the 281 clinical sera samples tested.  
For the serum samples with categorical data available their corresponding CIE assay 
and ELISA results were grouped together into case groups. Case group 1(categorical 
groupings consistent with SS) consisted of samples categorised 1-4 (refer to section 
2.13.3 for explanation of categories); Case group 2 (categorical grouping consistent 
with other CTD) consisted of samples categorised 5 and 6; Case group 3 (control 
group) consisted of samples in category 7. The results of the clinical sera sample CIE 
assays and ELISAs in Case groups 1 and 2 were cross reference with the results in 
Case group 3 to determine the diagnostic specificity and sensitivity, PLR and NLR of 
the CIE assays and ELISAs. 
 
When examining the performance using Group 1 data the diagnostic specificity and 
positive likelihood ratio (PLR) values of the SSA CIE assay were superior to those of 
the ELISA, while diagnostic sensitivity and the negative likelihood ratio (NLR) values 
were approximately the same. The sensitivity (70.8 %), specificity (90.2%), PLR 
(7.24), and NLR (0.32) of the SSA CIE assay indicate that it is a highly accurate 
assay for the detection of SS. These results differ to those reported by Phan et al 
(2002) which had the sensitivity for CIE and ELISA between 85-90% and 90-97% 
respectively and for the specificity for CIE and ELISA between 50-60% and 45-50% 
respectively. Both this study and the study by Phan et al (2002) demonstrate that 
there are few differences between the sensitivity and specificity of CIE and ELISA. 
This lack of difference indicates that the high specificity of novel CIE is likely due to 
the sample set used to assess the CIE assay and ELISA. These observations, along 
with the strong inter-rater agreement between the SSA CIE assay and ELISA 
suggests, that the SSA CIE assay maybe a suitable replacement for ELISA as a 
diagnostic tool for the identification of anti-SSA antibodies and Sjogren’s syndrome. 
Further, evaluation with a different and possibly larger sample set will be needed to 
assess whether the high specificity of the novel CIE assay is due to the sample set 
used to evaluate or to the inherent methodology of the technique.   
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Group 1 data was used to compare the RNP/Sm CIE assay and ELISA. The 
statistical measures of assay accuracy (diagnostic specificity and sensitivity, PLR, 
and NLR) for the RNP/Sm CIE assay and ELISA were approximately the same. 
However the values of the statistics for the ELISA were superior to those of CIE 
assay. Thus there is little evidence for clinical utility for this RNP/Sm CIE assay. 
 
Examining Group 1 data, the diagnostic specificities for the SSB CIE assay (98.9%) 
and Sm (97.8%) CIE assay were higher than that of their respective ELISAs (89.1%, 
and 85.9% respectively). The diagnostic sensitivities for the SSB CIE assay (16.7%) 
and Sm (12.5%) CIE assay were much lower than that of their respective ELISAs 
(54.2%, and 33.3% respectively). The PLR of the SSB CIE assay (15.33) was 
approximately 3 times that of its respective ELISA (4.98), and the PLR of the Sm CIE 
assay (5.75) was approximately twice that of its respective ELISA (2.36). Compared 
to Phan et al (2002) the sensitivity for CIE and ELISA for SSB was between 70-80% 
and 75-85% respectively and for the specificity for CIE and ELISA between 60-70% 
and 50-60% respectively. These results indicate that for the SSB and Sm CIE assays 
there would be a low occurrence of false positives and that these assays would be 
suitable as secondary confirmatory diagnostic assays for the identification of their 
respective ENA antibodies. Again, the results from Phan et al (2002) show few 
differences between the sensitivity and specificity of CIE and ELISA. In terms of the 
specificity determinied in this study this is also true. However there is a clear 
difference in sensitivity between the CIE and ELISA that is not seen in the study 
Phan by et al. This difference, along with the low agreement between the two assays 
indicates that there is some difference between the novel CIE assay and the ELISA 
that is likely not simply due to the sample set used to evaluate them. There was no 
reported data for the diagnostic sensitivity and specificity for SS as relates to Sm, as 
Sm is not considered a marker for SS. Again these results emphasise the need to 
further evaluate the novel CIE assays. 
 
When examining the CIE assays and ELISAs that using Case group 2 data does not 
change the diagnostic specificities for all assays the values for Case group 3 (the 
control group) have not changed. The sensitivity for all assays is low (less than 22%) 
and the values of the PLR and NLR ratio for all CIE and ELISA assays in Case group 
2 tend towards 1. Thus from the predictive value of either the CIE assays or the 
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ELISAs for other connective tissue diseases cannot be inferred. This may be due to 
the sample set tested being to small and/or the clinical data provided which 
essentially groups patients into other connective tissue disease. A clinical data set 
that indicated specifically what other connective tissue disease the patient symptoms 
indicated would be preferred to the current clinical data. Better yet would be to 
assess the diagnostic value of the assays by performing a longitudinal study in a 
clinical laboratory.   
 
4.3 RNP/Sm DID assay 
As it appears that the novel RNP/Sm CIE assay may not be suitable for use as a 
diagnostic tool, an alternative use for the D488-labelled RNP/Sm antigen was 
examined in the form of a DID assay. A series of experiment were performed to 
determine if there was a possibility of using D488-labelled RNP/Sm antigen for DID. 
For the 8 clinical samples and 20 Arotec internal standards tested those sera which 
were anti-RNP/Sm positive produced positive results by DID and those which were 
anti-RNP/Sm negative produced negative results by DID. Also the analytical 
sensitivity of this RNP/Sm DID assay was examined. A 1/8 sera dilution was the limit 
of detection and is notably less sensitive than that of the CIE assay. Promisingly 
these results indicate that a DID assay using D488-labelled RNP/Sm antigen could 
be used for the detection of anti-RNP/Sm serum antibodies. 
 84 
5. Conclusions and Future Work 
The central aim of this project to develop and validate a novel counter 
immunoelectrophoresis (CIE) assay that uses fluorescently labelled ENAs to detect 
ENA antibodies in patient serum was achieved for the SSA, SSB, and Sm antigens. 
 
Optimisation of CIE assay conditions for the detection ANA to each of the D488-
labelled ENAs SSA, SSB, RNP/Sm, and Sm was successful. Assay conditions 
optimised were flurophore type, gel composition, buffer composition, antigen 
concentration, the running time, and analytical specificity. The CIE assays were 
highly specific, and their accuracy was comparable if not superior to that of ELISA.   
 
The SSA CIE assay results suggest that this assay maybe a suitable replacement for 
ELISA as a diagnostic tool for the identification of anti-SSA antibodies and Sjogren’s 
syndrome. The SSB and Sm CIE assay results suggest that these assays would be 
suitable as secondary confirmatory diagnostic assays for the identification of their 
respective ENA antibodies. Although, results are promising further performance 
evaluation of the assays is necessary. This would require assessment of the assays 
as part of a longitudinal study within a routine diagnostic laboratory where patient 
outcome is tracked. A study of this type is required to provide a more accurate clinical 
data set for the assessment of the assays accuracy and to then compare these 
results alongside the laboratory’s current diagnostic testing methods. 
 
The D488-labelled RNP/Sm CIE assay was not suitable for use as a diagnostic tool. 
This was because it results were less accurate than ELISA, and it produced a low 
background in the negative control which made it difficult to objectively interpret the 
results of low titer plasma samples. However, the D488-labelled RNP/Sm may make 
a suitable antigen for DID as the preliminary results suggest. Further evaluation of 
the RNP/Sm DID assay with a greater number of samples is required for statistical 
analysis of its predictive accuracy.   
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Appendix 1 
Experiment A1 
Aim To examine what effect of serum age has on the outcome of a CIE assay replicate 
experiments were performed using a sera dilution series 
 
Method Three 2-fold sera dilution series (range 1/2 to 1/256) were created using Sm 
positive sera and unreactive sera (negative control). Using the dilution series and D488-
labelled Sm antigen at a concentration of 20 ng/µl a CIE assay was performed. The 
dilution series was stored at 4°C for 4 months and the CIE assay repeated. All CIE assays 
were performed using Apparatus 3 and the standard CIE method. 
 
Results Examining the precipitin bands in lane 5 (Fig. A1): when the serum was first run 
(0 months) at the endpoint of the assay (50 min runtime) a strong precipitin band half way 
between the Ag and Ab wells was observed. When the sera was run again (4 months) at 
the endpoint (50 min runtime) of the assay, the precipitin band was located slightly below 
the Ag well. If the CIE assay is run for a further 5 min the precipitin band migrates towards 
the cathode and past the Ag wells. 
Discussion These results suggest that as sera ages it produces a weaker more diffuse 
precipitate that can also migrate towards the cathode (towards the Ag well). This is likely 
due to the breakdown of either the serum antibodies and/or the serum proteins that assist 
precipitate formation. Notably, this effect seems to decrease as the titer of the sera 
decreases. This suggests that breakdown products are interacting and blocking the 
antigen interaction sites. Thus in antigen excess there are an increased number of 
unblocked interaction sites and therefore precipitate formation is restored.  
It is also worth noting that when the assay was run for a period longer than 50 min the 
precipitin band ran past the Ag well in lane 5 giving the impression of a negative result. 
This highlights the importance of having a stringent assay runtime. 
 
 
  
 
 
Figure A1 Sm sera titrations at 0 and 4 months 
 
 
 
 
 
 
 
Figure A1 
Replicate CIE assays performed with the same sera dilution series 4 months 
apart. In the Ag wells 5 µl antigen was loaded into each well. A sera titration 
series was loaded into the Ab wells; Lane 1 negative control, Lanes 2-5 2-fold 
sera dilutions 1/16 to 1/2, Lane 6 positive control. Using an amber filter under 
blue light excitation the precipitin reaction was observed as bright horizontal 
bands. 
 
